<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gaucher" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gaucher</book-part-id>
      <title-group>
        <title>Gaucher Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: Glucocerebrosidase Deficiency, Glucosylceramidase Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pastores</surname>
            <given-names>Gregory M</given-names>
          </name>
          <degrees>MD</degrees>
          <email>Gregory.Pastores@yale.edu</email>
          <aff>Department of Medicine<break/>Yale University School of Medicine<break/>New Haven, Connecticut</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hughes</surname>
            <given-names>Derralynn A</given-names>
          </name>
          <degrees>MA, DPhil, FRCP, FRCPath</degrees>
          <aff>Senior Lecturer in Haematology, Department of Academic Haematology <break/>Royal Free and University College Medical School <break/>London, United Kingdom</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2000-07-27" date-type="created">
          <day>27</day>
          <month>7</month>
          <year>2000</year>
        </date>
        <date iso-8601-date="2013-09-19" date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date iso-8601-date="2015-02-26" date-type="revised">
          <day>26</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="drd" document-type="chapter">GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="geleophys-dysp" document-type="chapter">Geleophysic Dysplasia</related-object>
      <abstract id="gaucher.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of GD relies on demonstration of deficient glucocerebrosidase (glucosylceramidase) enzyme activity in peripheral blood leukocytes or other nucleated cells. Carrier testing by assay of enzyme activity is unreliable because of overlap in enzyme activity between carriers and non-carriers. Identification of two disease-causing alleles in <italic toggle="yes">GBA</italic>, the only gene in which pathogenic variants are known to cause GD, provides additional confirmation of the diagnosis. However, given the broad heterogeneity in causative pathogenic variants, biochemical testing should be considered in individuals in whom genetic testing identifies a novel <italic toggle="yes">GBA</italic> pathogenic variant.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: When possible, management by a multidisciplinary team at a Comprehensive Gaucher Center. For persons not receiving enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), symptomatic treatment includes partial or total splenectomy for massive splenomegaly and thrombocytopenia. Supportive care for all affected individuals may include: transfusion of blood products for severe anemia and bleeding, analgesics for bone pain, joint replacement surgery for relief from chronic pain and restoration of function, and oral bisphosphonates and calcium for osteoporosis.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: ERT is usually well tolerated and provides sufficient exogenous enzyme to overcome the block in the catabolic pathway, clearing the stored substrate, GL1, and thus reversing hematologic and liver/spleen involvement. Although bone marrow transplantation (BMT) had been undertaken in individuals with severe GD, primarily those with chronic neurologic involvement (GD type 3), this procedure has been largely superseded by ERT. Miglustat may be indicated in symptomatic individuals with GD type 1 who are not able to receive ERT.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: The use of anticoagulants in individuals with severe thrombocytopenia and/or coagulopathy should be discussed with a hematologist to avoid the possibility of excessive bleeding.</p>
          <p><italic toggle="yes">Surveillance</italic>: Recommendations for comprehensive serial monitoring have been published by the International Collaborative Gaucher Group Registry (ICGG) and other groups.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Nonsteroidal anti-inflammatory drugs (NSAIDs) in individuals with moderate to severe thrombocytopenia.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: It is appropriate to offer testing to asymptomatic at-risk relatives so that those with glucocerebrosidase enzyme deficiency, or two disease-causing alleles, can benefit from early diagnosis and treatment if indicated.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Gaucher disease (GD) is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Targeted mutation analysis can be used to detect carriers in high-risk populations (e.g., Ashkenazi Jewish persons). Because the carrier frequency for GD in certain populations is high (e.g., 1:18 in individuals of Ashkenazi Jewish heritage) and the N370S/N370S phenotype is variable, individuals who undergo carrier testing may be identified as being homozygous. Prenatal testing for pregnancies at increased risk is possible using assay of glucocerebrosidase enzymatic activity and molecular genetic testing when both disease-causing mutations in a family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gaucher.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="gaucher.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_gaucher.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gaucher Disease: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_gaucher.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Gaucher disease type 1</p>
                    </list-item>
                    <list-item>
                      <p>Gaucher disease type 2 (acute)</p>
                    </list-item>
                    <list-item>
                      <p>Gaucher disease type 3 (subacute/chronic)</p>
                    </list-item>
                    <list-item>
                      <p>Gaucher disease, perinatal-lethal form</p>
                    </list-item>
                    <list-item>
                      <p>Gaucher disease, cardiovascular form</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="gaucher.Diagnosis">
        <title>Diagnosis</title>
        <sec id="gaucher.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Gaucher disease (referred to as GD in this entry) is suspected in individuals with characteristic bone lesions, hepatosplenomegaly and hematologic changes, or signs of CNS involvement [<xref ref-type="bibr" rid="gaucher.REF.mistry.2011.110">Mistry et al 2011</xref>]. Clinical findings alone are not diagnostic.</p>
        </sec>
        <sec id="gaucher.Testing">
          <title>Testing</title>
          <p>
            <bold>Assay of glucocerebrosidase (glucosylceramidase) enzyme activity</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Affected individuals.</bold> The most efficient and reliable method of establishing the diagnosis of GD is the assay of glucocerebrosidase enzyme activity in peripheral blood leukocytes or other nucleated cells. The test is a fluorometric assay and uses the substrate 4-methylumbelliferyl-&#x003b2;-D-glucopyranoside. In affected individuals, glucocerebrosidase enzyme activity in peripheral blood leukocytes is 0%-15% of normal activity. Note: The results of biochemical testing do not reliably enable prediction of disease severity or subtype.</p>
            </list-item>
            <list-item>
              <p><bold>Carriers.</bold> Glucocerebrosidase enzyme activity is unreliable for carrier detection given the overlap in enzyme activity levels between carriers and non-carriers.</p>
            </list-item>
          </list>
          <p><bold>Bone marrow examination.</bold> Affected individuals may first be suspected of having GD following bone marrow examination for GD-related manifestations (e.g., anemia, thrombocytopenia, and/or splenomegaly) [<xref ref-type="bibr" rid="gaucher.REF.beutler.2006.103">Beutler 2006</xref>]. Bone marrow examination reveals the presence of lipid-engorged macrophages ('Gaucher cells'), characterized by a fibrillary, 'crumpled silk' appearance to the cytoplasm and an eccentrically placed nucleus. This material stains positively with periodic acid-Schiff (PAS) reagent. Studies have indicated that Gaucher cells have a cellular phenotype akin to alternatively activated macrophages [<xref ref-type="bibr" rid="gaucher.REF.boven.2004.359">Boven et al 2004</xref>].</p>
          <p>Note: The changes described are nonspecific, and bone marrow examination is not a reliable diagnostic test.</p>
          <sec id="gaucher.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">GBA</italic> is the only gene in which mutation is known to cause GD.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="gaucher.T.summary_of_molecular_genetic_t" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Gaucher Disease</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GBA</italic>
                    </td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">Targeted mutation analysis</td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Four common variants&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">89%&#x000a0;<sup>5,&#x000a0;6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Other variants&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~98%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~99%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Partial and whole-gene deletion&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_gaucher.T.summary_of_molecular_genetic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown; likely &#x0003c;1%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="gaucher.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="gaucher" object-id="gaucher.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="gaucher.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="gaucher.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="gaucher.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="gaucher.TF.1.4">
                  <label>4. </label>
                  <p><xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">84GG</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">IVS2+1</xref>. Historical names for variants are given in the text. See <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">Table 5</xref> for variant names according to the current standards of nomenclature.</p>
                </fn>
                <fn id="gaucher.TF.1.5">
                  <label>5. </label>
                  <p>See <xref ref-type="table" rid="gaucher.T.proportion_of_individuals_with">Table 2</xref>.</p>
                </fn>
                <fn id="gaucher.TF.1.6">
                  <label>6. </label>
                  <p>Four variants account for approximately 90% of the pathogenic variants in the Ashkenazi Jewish population. In non-Jewish populations, the same four alleles account for approximately 50%-60% of pathogenic variants. Non-Jewish individuals with GD tend to be compound heterozygotes with one common and one 'rare' pathogenic variant (<xref ref-type="table" rid="gaucher.T.proportion_of_individuals_with">Table 2</xref>) or a unique pathogenic variant.</p>
                </fn>
                <fn id="gaucher.TF.1.7">
                  <label>7. </label>
                  <p>Mutation panel may vary by laboratory.</p>
                </fn>
                <fn id="gaucher.TF.1.8">
                  <label>8. </label>
                  <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="gaucher.TF.1.9">
                  <label>9. </label>
                  <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="gaucher.TF.1.10">
                  <label>10. </label>
                  <p>Deletions of 3925 bp of exons 1-2 and 5&#x02019;UTR and of the whole gene have been reported [<xref ref-type="bibr" rid="gaucher.REF.beutler.1994.212">Beutler &#x00026; Gelbart 1994</xref>, <xref ref-type="bibr" rid="gaucher.REF.cozar.2011.226">Cozar et al 2011</xref>]</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="gaucher.T.proportion_of_individuals_with" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Proportion of Individuals with <italic toggle="yes">GBA</italic> Pathogenic Variants Using the Panel of Four Common Variants</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Affected Individuals&#x000a0;<sup>2,&#x000a0;3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/N370S</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">29%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/?</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/L444P</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">16%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/84GG</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">12%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P/L444P</xref>&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P/?</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/IVS2+1</xref>
                    </td>
                    <td headers="hd_h_gaucher.T.proportion_of_individuals_with_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3%</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="gaucher.TF.2.1">
                  <label>1. </label>
                  <p><xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">Table 5</xref> provides the variant name and nucleotide changes according to current nomenclature guidelines.</p>
                </fn>
                <fn id="gaucher.TF.2.2">
                  <label>2. </label>
                  <p>Based on data from 1097 individuals in the Gaucher Registry (International Collaborative Gaucher Group [October 1999]). In this population, 94% of individuals had type 1, 1% had type 2, and 5% type 3.</p>
                </fn>
                <fn id="gaucher.TF.2.3">
                  <label>3. </label>
                  <p>GD mutation detection rates based on sequence analysis available through the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.registrynxt.com/Gaucher/Pages/Home.aspx">ICGG Registry Program</ext-link> (registration required)</p>
                </fn>
                <fn id="gaucher.TF.2.4">
                  <label>4. </label>
                  <p>Recombinant (Rec) alleles (i.e., the RecNciI allele; see <xref ref-type="sec" rid="gaucher.Molecular_Genetics">Molecular Genetics</xref>) contain two to four single nucleotide variants (including <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref>) that arise as a result of gene rearrangements between exons 9 and 10 of the functional gene and pseudogene. Thus, testing for the L444P variant alone does not allow distinction of the isolated L444P allele from Rec alleles, and may lead to an error in genotype designation [<xref ref-type="bibr" rid="gaucher.REF.tayebi.2003a.519">Tayebi et al 2003a</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="gaucher.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Assay of glucocerebrosidase enzyme activity in leukocytes or other nucleated cells is the confirmatory diagnostic test.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing (see <bold>Molecular genetic testing strategy</bold>) and the identification of two disease-causing alleles provide an alternative means of confirming the diagnosis. There is broad heterogeneity in causative variants; in individuals in whom genetic testing identifies a novel <italic toggle="yes">GBA</italic> variant, biochemical testing to confirm the diagnosis should be considered.</p>
            </list-item>
            <list-item>
              <p>As the diagnosis of GD can be confirmed through biochemical or molecular testing performed on peripheral blood leukocytes, it is not necessary to perform a bone marrow examination.</p>
            </list-item>
          </list>
          <p>
            <bold>Molecular genetic testing strategy</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Targeted analysis for pathogenic variants in a proband originally diagnosed by biochemical testing may be considered for genetic counseling purposes, primarily to identify the pathogenic variants and permit carrier detection among at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of the <italic toggle="yes">GBA</italic> coding region may be used to detect pathogenic variants in affected individuals in whom targeted analysis has identified only a single pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If sequence analysis fails to detect the second pathogenic variant, deletion/duplication analysis may be appropriate.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="gaucher.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="gaucher.Clinical_Description">
          <title>Clinical Description</title>
          <p>Gaucher disease (GD) encompasses a spectrum of clinical findings from a perinatal-lethal form to an asymptomatic form. However, for the purposes of determining prognosis and management, the classification of GD by clinical subtype is still useful in describing the wide range of clinical findings and broad variability in presentation. Three major clinical types are delineated by the absence (type 1) or presence (types 2 and 3) of primary central nervous system involvement (<xref ref-type="table" rid="gaucher.T.gaucher_disease_clinical_subty">Table 3</xref>).</p>
          <table-wrap id="gaucher.T.gaucher_disease_clinical_subty" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Gaucher Disease: Clinical Subtypes</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Subtype</th>
                  <th id="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Primary CNS Involvement</th>
                  <th id="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Bone Disease</th>
                  <th id="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Other</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 1</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Splenomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Hepatomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Cytopenia</p>
                      </list-item>
                      <list-item>
                        <p>Pulmonary disease</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 2 <break/>(acute or infantile)</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Bulbar signs</p>
                      </list-item>
                      <list-item>
                        <p>Pyramidal signs</p>
                      </list-item>
                      <list-item>
                        <p>Cognitive impairment</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Hepatomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Splenomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Cytopenia</p>
                      </list-item>
                      <list-item>
                        <p>Pulmonary disease</p>
                      </list-item>
                      <list-item>
                        <p>Dermatologic changes</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type 3 <break/>(subacute; juvenile)</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Oculomotor apraxia</p>
                      </list-item>
                      <list-item>
                        <p>Seizures</p>
                      </list-item>
                      <list-item>
                        <p>Progressive myoclonic epilepsy</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Hepatomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Splenomegaly</p>
                      </list-item>
                      <list-item>
                        <p>Cytopenia</p>
                      </list-item>
                      <list-item>
                        <p>Pulmonary disease</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Perinatal-lethal form</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Pyramidal signs</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">No</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Ichthyosiform or collodion skin changes</p>
                      </list-item>
                      <list-item>
                        <p>Nonimmune hydrops fetalis</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cardiovascular form</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Oculomotor apraxia</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Yes</td>
                  <td headers="hd_h_gaucher.T.gaucher_disease_clinical_subty_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Calcification of mitral and aortic valves</p>
                      </list-item>
                      <list-item>
                        <p>Corneal opacity</p>
                      </list-item>
                      <list-item>
                        <p>Mild splenomegaly</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <sec id="gaucher.Type_1_GD">
            <title>Type 1 GD</title>
            <p><bold>Bone disease.</bold> Clinical or radiographic evidence of bone disease occurs in 70%-100% of individuals with type 1 GD. Bone disease ranges from asymptomatic osteopenia to focal lytic or sclerotic lesions and osteonecrosis [<xref ref-type="bibr" rid="gaucher.REF.wenstrup.2002.a2">Wenstrup et al 2002</xref>]. Bone involvement, which may lead to acute or chronic bone pain, pathologic fractures, and subchondral joint collapse with secondary degenerative arthritis, is often the most debilitating aspect of type 1 GD [<xref ref-type="bibr" rid="gaucher.REF.pastores.2000.175">Pastores et al 2000</xref>].</p>
            <p>Acute bone pain manifests as 'bone crises' or episodes of deep bone pain that are usually confined to one extremity or joint [<xref ref-type="bibr" rid="gaucher.REF.cohen.2003.838">Cohen 2003</xref>] and are often accompanied by fever and leukocytosis but sterile blood culture. The affected region may be swollen and warm to touch; imaging studies may reveal signal abnormalities consistent with localized edema or hemorrhage; x-rays may show periosteal elevation ('pseudo-osteomyelitis') [<xref ref-type="bibr" rid="gaucher.REF.pastores.2005.70">Pastores &#x00026; Meere 2005</xref>].</p>
            <p>Conventional radiographs (x-rays) may reveal undertubulation (Erhlenmeyer flask configuration) noted in the distal femur and endosteal scalloping as a sign of bone marrow infiltration. MRI reveals the extent of marrow involvement and the presence of fibrosis and/or infarction. In general, marrow infiltration extends from the axial to the appendicular skeleton, and greater involvement is often seen in the lower extremities and proximal sites of an affected bone. The epiphyses are usually spared, except in advanced cases. Bone densitometry studies enable quantitative assessment of the degree of osteopenia.</p>
            <p>Bone disease in GD may not correlate with the severity of hematologic or visceral problems.</p>
            <p><bold>Secondary neurologic disease in type 1 GD.</bold> Although individuals with type 1 GD do not have primary CNS disease, neurologic complications (spinal cord or nerve root compression) may occur secondary to bone disease (e.g., severe osteoperosis with vertebral compression; emboli following long bone fracture), or coagulopathy (e.g., hematomyelia) [<xref ref-type="bibr" rid="gaucher.REF.pastores.2003.641">Pastores et al 2003</xref>].</p>
            <p>The incidence of peripheral neuropathy may be higher than previously recognized [<xref ref-type="bibr" rid="gaucher.REF.halperin.2007.275">Halperin et al 2007</xref>, <xref ref-type="bibr" rid="gaucher.REF.capablo.2008.219">Capablo et al 2008</xref>].</p>
            <p><bold>Hepatosplenomegaly.</bold> The spleen is enlarged (i.e., 1500-3000 cc in size, compared to 50-200 cc in the average adult) with resultant hypersplenism associated with pancytopenia (i.e., anemia, leukopenia, and thrombocytopenia). Infarction of the spleen can result in acute abdominal pain. Rarely, acute surgical emergencies may arise because of splenic rupture [<xref ref-type="bibr" rid="gaucher.REF.stone.2000b.140">Stone et al 2000b</xref>].</p>
            <p>Liver enlargement is common, although cirrhosis and hepatic failure are rare.</p>
            <p><bold>Cytopenias.</bold> Cytopenia is almost universal in untreated GD. Anemia, thrombocytopenia, and leukopenia may be present simultaneously or independently [<xref ref-type="bibr" rid="gaucher.REF.zimran.2005.151">Zimran et al 2005</xref>]. The pattern of cytopenia in GD is dependent on spleen status.</p>
            <p>Low platelet count may result from hypersplenism, splenic pooling of platelets, or marrow infiltration or infarction. Immune thrombocytopenia has also been reported and should be excluded in individuals with persistent thrombocytopenia despite GD-specific therapy. Thrombocytopenia may be associated with easy bruising or overt bleeding, particularly with trauma, surgery, or pregnancy. The risk for bleeding may be increased in the presence of clotting abnormalities.</p>
            <p>Anemia may result from hypersplenism, hemodilution (e.g., pregnancy), iron deficiency or B<sub>12</sub> deficiency and, in advanced disease, decreased erythropoiesis as a result of bone marrow failure from Gaucher cell infiltration or medullary infarction.</p>
            <p>Leukopenia is rarely severe enough to require intervention. Deficient neutrophil function has been reported.</p>
            <p><bold>Coagulation abnormalities.</bold> Acquired coagulation factor deficiencies include low-grade disseminated intravascular coagulation and specific inherited coagulation factor deficiencies (e.g., factor XI deficiency among Ashkenazi Jews). An investigation of Egyptian individuals with type 1 GD revealed a wide variety of coagulation factor abnormalities (fibrinogen, factor II, VII, VIII, X, XII) [<xref ref-type="bibr" rid="gaucher.REF.deghady.2006.411">Deghady et al 2006</xref>]. Abnormal platelet aggregation may contribute to bleeding diathesis in the presence of normal platelet counts.</p>
            <p><bold>Pulmonary involvement.</bold> The following can be observed:</p>
            <list list-type="bullet">
              <list-item>
                <p>Interstitial lung disease</p>
              </list-item>
              <list-item>
                <p>Alveolar/lobar consolidation</p>
              </list-item>
              <list-item>
                <p>Pulmonary hypertension; well documented in individuals with liver disease and presumably the result of inability to detoxify gut-derived factors, which somehow adversely affect the pulmonary endothelium with resultant pulmonary hypertension. Pulmonary hypertension can also occur in individuals with GD without liver disease [<xref ref-type="bibr" rid="gaucher.REF.mistry.2002.91">Mistry et al 2002</xref>].</p>
              </list-item>
            </list>
            <p>Dyspnea and cyanosis with digital clubbing attributed to hepatopulmonary syndrome have been described in individuals with liver dysfunction, often caused by an intercurrent disease (e.g., viral hepatitis).</p>
            <p>Those individuals with type 1 GD without evident lung involvement who limit physical exertion because of easy fatigability may have impaired circulation [<xref ref-type="bibr" rid="gaucher.REF.miller.2003.368">Miller et al 2003</xref>].</p>
            <p><bold>Pregnancy and childbirth.</bold> Except in women with significant pulmonary hypertension, pregnancy is not contraindicated in GD.</p>
            <p>In some women the diagnosis of GD is first made in pregnancy because of exacerbation of hematologic features.</p>
            <p><bold>Malignancy.</bold> Epidemiologic studies have suggested elevated risk of certain malignancies in GD including the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Multiple myeloma [<xref ref-type="bibr" rid="gaucher.REF.rosenbloom.2005.4569">Rosenbloom et al 2005</xref>]</p>
              </list-item>
              <list-item>
                <p>Hepatocellular carcinoma [<xref ref-type="bibr" rid="gaucher.REF.de_fost.2006.53">de Fost et al 2006</xref>]</p>
              </list-item>
              <list-item>
                <p>Non-Hodgkins lymphoma, malignant melanoma, and pancreatic cancer [<xref ref-type="bibr" rid="gaucher.REF.landgren.2007.1189">Landgren et al 2007</xref>]</p>
              </list-item>
            </list>
            <p>Except in the case of multiple myeloma, other reports have failed to find these associations. The basis for increased risk for multiple myeloma is not known.</p>
            <p><bold>Immunologic abnormalities.</bold> Children or adults may have polyclonal gammopathy [<xref ref-type="bibr" rid="gaucher.REF.wine.2007.451">Wine et al 2007</xref>]. An increased incidence of monoclonal gammopathy has been reported in adults [<xref ref-type="bibr" rid="gaucher.REF.brautbar.2004.214">Brautbar et al 2004</xref>]. Affected individuals also exhibit altered cellular immune profiles with increased peripheral blood NKT lymphocytes and reduced numbers of functionally normal dendritic cells [<xref ref-type="bibr" rid="gaucher.REF.lalazar.2006.1249">Lalazar et al 2006</xref>, <xref ref-type="bibr" rid="gaucher.REF.micheva.2006.298">Micheva et al 2006</xref>].</p>
            <p><bold>Metabolic abnormalities.</bold> GD is associated with metabolic abnormalities including high resting energy expenditures (possibly the result of elevated cytokine levels) and low circulating adiponectin and peripheral insulin. The hypermetabolic state is not associated with altered thyroid hormone resistance [<xref ref-type="bibr" rid="gaucher.REF.langeveld.2007a.985">Langeveld et al 2007a</xref>, <xref ref-type="bibr" rid="gaucher.REF.langeveld.2007b.314">Langeveld et al 2007b</xref>, <xref ref-type="bibr" rid="gaucher.REF.langeveld.2008.428">Langeveld et al 2008</xref>].</p>
            <p>Serum concentrations of angiotensin-converting enzyme, tartrate-resistant acid phosphatase, ferritin, chitotriosidase, and PARC/CCL18 are usually elevated. Serum concentrations of total and HDL cholesterol are often low.</p>
            <p>Abnormalities in the concentration of certain bone markers have been found in some individuals with GD in serum (e.g., osteocalcin, bone-specific alkaline phosphatase, macrophage inhibitory protein-1 alpha and beta) and urine (e.g., urinary hydroxyproline, free deoxypyridinoline, calcium); however, the utility of these findings in clinical practice is undetermined [<xref ref-type="bibr" rid="gaucher.REF.drugan.2002.13">Drugan et al 2002</xref>, <xref ref-type="bibr" rid="gaucher.REF.ciana.2003.185">Ciana et al 2003</xref>, <xref ref-type="bibr" rid="gaucher.REF.van_breemen.2007.788">van Breemen et al 2007</xref>].</p>
            <p><bold>Psychological complications.</bold> Persons with GD exhibit moderate to severe psychological complications including somatic concerns and depressed mood [<xref ref-type="bibr" rid="gaucher.REF.packman.2006.99">Packman et al 2006</xref>].</p>
            <p>
              <bold>Other</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Cholelithiasis occurs in a significant proportion of adults with GD (21/66 cases) [<xref ref-type="bibr" rid="gaucher.REF.rosenbaum.2002.21">Rosenbaum &#x00026; Sidransky 2002</xref>].</p>
              </list-item>
              <list-item>
                <p>Cardiac and renal complications are rare.</p>
              </list-item>
            </list>
          </sec>
          <sec id="gaucher.Type_2_GD__Type_3_GD_Primary_Neu">
            <title>Type 2 GD / Type 3 GD (Primary Neurologic Disease)</title>
            <p><bold>Neurologic disease.</bold> Previously, affected individuals were classified into type 2 or type 3 GD based on the age of onset of neurologic signs and symptoms and the rate of disease progression. Children with onset before age two years with a rapidly progressive course, limited psychomotor development, and death by age two to four years were classified as having type 2 GD. Individuals with type 3 GD may have onset before age two years but often have a more slowly progressive course, with life span extending into the third or fourth decade in some cases. However, these distinctions are not absolute and it is increasingly recognized that neuropathic GD represents a phenotypic continuum, ranging from abnormalities of horizontal ocular saccades at the mild end to hydrops fetalis at the severe end [<xref ref-type="bibr" rid="gaucher.REF.gokeralpan.2003.273">Goker-Alpan et al 2003</xref>].</p>
            <p>Bulbar signs include stridor, squint, and swallowing difficulty.</p>
            <p>Pyramidal signs include opisthotonus, head retroflexion, spasticity, and trismus.</p>
            <p>Oculomotor apraxia, saccadic initiation failure, and opticokinetic nystagmus are common [<xref ref-type="bibr" rid="gaucher.REF.harris.1999.289">Harris et al 1999</xref>]. Oculomotor involvement may be found as an isolated sign of neurologic disease in individuals with a chronic progressive course and severe systemic involvement (e.g., massive hepatosplenomegaly).</p>
            <p>Generalized tonic-clonic seizures and progressive myoclonic epilepsy have been observed in some individuals [<xref ref-type="bibr" rid="gaucher.REF.verghese.2000.389">Verghese et al 2000</xref>, <xref ref-type="bibr" rid="gaucher.REF.frei.2002.41">Frei &#x00026; Schiffmann 2002</xref>].</p>
            <p>Dementia and ataxia have been observed in the later stages of chronic neurologic disease.</p>
            <p>Brain stem auditory evoked response (BAER) testing may reveal abnormal wave forms (III and IV). MRI of the brain may show mild cerebral atrophy. (A normal EEG, BAER, or brain MRI does not exclude neurologic involvement.)</p>
            <p><bold>Perinatal-lethal form.</bold> The perinatal-lethal form is associated with hepatosplenomegaly, pancytopenia, and microscopic skin changes (i.e., abnormalities in the stratum corneum attributed to altered glucosylceramide-to-ceramide ratio) and may present clinically with ichthyosiform or collodion skin abnormalities or as nonimmune hydrops fetalis [<xref ref-type="bibr" rid="gaucher.REF.orvisky.2002.262">Orvisky et al 2002</xref>]. Arthrogryposis and distinctive facial features are seen in 35%-43% [<xref ref-type="bibr" rid="gaucher.REF.mignot.2003.338">Mignot et al 2003</xref>].</p>
            <p>Another rare severe variant of GD is associated with hydrocephalus, corneal opacities, deformed toes, gastroesophageal reflux, and fibrous thickening of splenic and hepatic capsules [<xref ref-type="bibr" rid="gaucher.REF.stone.2000c.181">Stone et al 2000c</xref>, <xref ref-type="bibr" rid="gaucher.REF.inui.2001.137">Inui et al 2001</xref>].</p>
            <p><bold>Cardiovascular form.</bold> Individuals homozygous for the D409H allele present with an atypical phenotype dominated by cardiovascular disease with calcification of the mitral and aortic valves [<xref ref-type="bibr" rid="gaucher.REF.bohlega.2000.261">Bohlega et al 2000</xref>]. Additional findings include mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia [<xref ref-type="bibr" rid="gaucher.REF.george.2001.360">George et al 2001</xref>].</p>
          </sec>
        </sec>
        <sec id="gaucher.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The amount of residual glucocerebrosidase enzyme activity as measured in vitro from extracts of nucleated cells does not correlate with disease type or severity.</p>
          <p>Genotype-phenotype correlations in GD are imperfect. Significant overlap in the clinical manifestations found between individuals with the various genotypes precludes specific counseling about prognosis in individual cases. At present the factors that influence disease severity or progression within particular genotypes are not known. Discordance in phenotype has been reported even among monozygotic twins [<xref ref-type="bibr" rid="gaucher.REF.lachmann.2004.199">Lachmann et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.biegstraaten.2011.39">Biegstraaten et al 2011</xref>].</p>
          <p>The following observations apply:</p>
          <p>
            <bold>Type 1 GD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with at least one <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S</xref> allele do not develop primary neurologic disease [<xref ref-type="bibr" rid="gaucher.REF.koprivica.2000.1777">Koprivica et al 2000</xref>]. However, the risk for Parkinson disease among individuals with GD is not precluded by the presence of an N370S allele.</p>
            </list-item>
            <list-item>
              <p>In general, individuals who are homozygous for the N370S variant tend to have milder disease than those who are compound heterozygous. It is suspected that a significant proportion of Ashkenazi Jewish individuals with this genotype may be asymptomatic and thus do not come to the attention of medical professionals [<xref ref-type="bibr" rid="gaucher.REF.azuri.1998.297">Azuri et al 1998</xref>]. However, surveillance is critical, as a proportion of these individuals do develop progressive disease [<xref ref-type="bibr" rid="gaucher.REF.taddei.2009.208">Taddei et al 2009</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Primary neurologic disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals who are homozygous for the <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref> variant tend to have severe disease, often with neurologic complications (i.e., types 2 and 3), although several individuals (including adults) with this genotype have had no overt neurologic problems. This variant results in an unstable enzyme with little or no residual activity. In a study of 31 individuals with type 2 GD, L444P accounted for 25 alleles (40%) [<xref ref-type="bibr" rid="gaucher.REF.stone.2000c.181">Stone et al 2000c</xref>]. The L444P variant occurred alone (9 alleles), with the E326K polymorphism (1 allele), and as part of a recombinant allele (15 alleles). In another study, homozygosity for the L444P variant was the most common genotype among individuals with type 3 GD (10/24 individuals, or 42%) [<xref ref-type="bibr" rid="gaucher.REF.koprivica.2000.1777">Koprivica et al 2000</xref>].</p>
            </list-item>
            <list-item>
              <p>In individuals with GD and myoclonic epilepsy, <xref ref-type="bibr" rid="gaucher.REF.park.2003.387">Park et al [2003]</xref> identified 14 genotypes (including the variants <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">V394L</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">G377S</xref>, and <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N188S</xref>) previously associated with non-neuronopathic GD, in combination with the variant <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref> and recombinant alleles that have been previously associated with neuropathic GD.</p>
            </list-item>
            <list-item>
              <p>A second variant (H255Q) occurring <italic toggle="yes">in cis</italic> with the <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">D409H</xref> variant has been identified among Greek and Albanian individuals. Homozygosity for the D409H/ H225Q allele has been associated with type 2 GD [<xref ref-type="bibr" rid="gaucher.REF.michelakakis.2006.591">Michelakakis et al 2006</xref>].</p>
            </list-item>
          </list>
          <p><bold>Perinatal-lethal form.</bold> Genotypic heterogeneity is significant in this rare subset of individuals. The following have been observed:</p>
          <list list-type="bullet">
            <list-item>
              <p>Homozygosity for recombinant alleles [<xref ref-type="bibr" rid="gaucher.REF.stone.2000a.f163">Stone et al 2000a</xref>]</p>
            </list-item>
            <list-item>
              <p>The mutant alleles <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">S196P</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">R131L</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">R120W</xref>, and <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">R257Q</xref> [<xref ref-type="bibr" rid="gaucher.REF.stone.2000a.f163">Stone et al 2000a</xref>]</p>
            </list-item>
            <list-item>
              <p>Compound heterozygosity for an insertion-type pathogenic variant and the pathogenic missense variant <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">R120Q</xref>, previously reported in an individual with type 1 GD [<xref ref-type="bibr" rid="gaucher.REF.felderhoffmueser.2004.138">Felderhoff-Mueser et al 2004</xref>]</p>
            </list-item>
          </list>
          <p><bold>Cardiovascular form.</bold> This phenotype has been described only in individuals who are homozygous for the D409H allele. The biochemical basis for the unique clinical features associated with this form is not fully delineated. It should be noted that homozygosity for the D409H/H255Q allele is associated with neuropathic type 2 GD and not the cardiovascular form (see <bold>Primary neurologic disease</bold> above).</p>
          <p><xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli"><bold>84GG </bold></xref><bold>and</bold>
<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli"><bold>IVS2+1</bold></xref></p>
          <list list-type="bullet">
            <list-item>
              <p>Despite the observed allele frequencies for the pathogenic variants 84GG and IVS2+1, no live-born homozygous for either variant has been identified. Thus, it is presumed that these genotypes are lethal.</p>
            </list-item>
            <list-item>
              <p>Children who are compound heterozygotes (i.e., 84GG/IVS2+1) have a subacute disease course with progressive pulmonary involvement and death in the first to second decade.</p>
            </list-item>
          </list>
          <p><bold>Other.</bold> Although it is likely that other factors including modifier genes that influence phenotypic expression exist, no mechanistic links have been demonstrated.</p>
          <list list-type="bullet">
            <list-item>
              <p>In individuals homozygous for the <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S</xref> allele, no correlation with clinical variability was observed with polymorphisms in the gene encoding glucosylceramide (glucocerebroside) synthase (the enzyme involved in the anabolic pathway or substrate synthesis) [<xref ref-type="bibr" rid="gaucher.REF.beutler.2002.986">Beutler &#x00026; West 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Non-pathogenic sequence variants have been described, but none is over- or underrepresented in individuals with severe disease as compared to those with mild disease [<xref ref-type="bibr" rid="gaucher.REF.beutler.2004.65">Beutler et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Certain missense variants lead to misfolding of the enzyme protein within the endoplasmic reticulum (ER) and its degradation. Variability in the rate of retention and degradation of the defective enzyme within the ER has been shown to correlate with disease severity [<xref ref-type="bibr" rid="gaucher.REF.ron.2005.2387">Ron &#x00026; Horowitz 2005</xref>]. The clinical usefulness of these observations remains to be determined.</p>
            </list-item>
            <list-item>
              <p>A genome-wide association study of Ashkenazi Jewish individuals with GD who are homozygous for the N370S allele indicated that changes in CLN8 expression may act as a genetic modifier, possibly mediated through sphingolipid signaling [<xref ref-type="bibr" rid="gaucher.REF.zhang.2012.377">Zhang et al 2012</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="gaucher.Prevalence">
          <title>Prevalence</title>
          <p>A study from Australia reported a disease frequency of 1:57,000 [<xref ref-type="bibr" rid="gaucher.REF.meikle.1999.249">Meikle et al 1999</xref>]; a similar study from the Netherlands reported 1.16:100,000 [<xref ref-type="bibr" rid="gaucher.REF.poorthuis.1999.151">Poorthuis et al 1999</xref>].</p>
          <p>A founder effect for specific alleles underlies the observed occurrence of GD in specific populations:</p>
          <list list-type="bullet">
            <list-item>
              <p>Ashkenazi Jewish, Spanish, and Portuguese (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S</xref>)</p>
            </list-item>
            <list-item>
              <p>Swedish (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref>)</p>
            </list-item>
            <list-item>
              <p>Jenin Arab, Greek, and Albanian (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">D409H</xref>). Among Greeks and Albanians, D409H has been found in <italic toggle="yes">cis</italic> with H255Q.</p>
            </list-item>
          </list>
          <p>Non-neuropathic GD (type 1) is prevalent in the Ashkenazi Jewish population, with a disease prevalence of 1:855 and an estimated carrier frequency of 1:18.</p>
          <p>The prevalence of neuropathic GD (types 2 and 3) varies across ethnic groups but appears to be higher among those who are not of European origin.</p>
        </sec>
      </sec>
      <sec id="gaucher.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>Parkinsonian features</bold> have been reported in a few individuals with type 1 GD; although studies suggest a possible cause-and-effect relationship rather than mere coincidence, the underlying basis remains to be established [<xref ref-type="bibr" rid="gaucher.REF.tayebi.2003b.104">Tayebi et al 2003b</xref>, <xref ref-type="bibr" rid="gaucher.REF.halperin.2006.426">Halperin et al 2006</xref>]. The following findings suggest that mutation of <italic toggle="yes">GBA</italic> and/or alterations in glucosylceramide metabolism may be a risk factor for parkinsonism [<xref ref-type="bibr" rid="gaucher.REF.sidransky.2005.302">Sidransky 2005</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>Brain pathology in a few individuals with type 1 GD (with and without parkinsonism and dementia) revealed astrogliosis as well as changes in the hippocampal regions. Brain pathology in individuals with type 2 and type 3 GD additionally revealed neuronal loss [<xref ref-type="bibr" rid="gaucher.REF.wong.2004.192">Wong et al 2004</xref>].</p>
          </list-item>
          <list-item>
            <p>Immunofluorescence studies on brain tissue samples from persons with parkinsonism associated with mutation of <italic toggle="yes">GBA</italic> showed that glucocerebrosidase was present in 32%-90% of Lewy bodies, some ubiquitinated and others non-ubiquitinated [<xref ref-type="bibr" rid="gaucher.REF.gokeralpan.2010.641">Goker-Alpan et al 2010</xref>]. Conversely, GBA enzyme activity was shown to be reduced in the substancia nigra in the brains of individuals with Parkinson disease (PD) in whom <italic toggle="yes">GBA</italic> pathogenic variants were not identified, confirming the relevance of enzyme function to the wider PD population.</p>
          </list-item>
          <list-item>
            <p>The precise risk for individuals with Gaucher disease of developing PD is not known, but has been variously estimated as 20- to 30-fold the risk of an individual in the general population [<xref ref-type="bibr" rid="gaucher.REF.bultron.2010.167">Bultron et al 2010</xref>, <xref ref-type="bibr" rid="gaucher.REF.mcneill.2012.853">McNeill et al 2012</xref>].</p>
          </list-item>
          <list-item>
            <p>Family studies suggest that the incidence of parkinsonism may be higher in obligate heterozygotes for GD [<xref ref-type="bibr" rid="gaucher.REF.tayebi.2003b.104">Tayebi et al 2003b</xref>, <xref ref-type="bibr" rid="gaucher.REF.halperin.2006.426">Halperin et al 2006</xref>].</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">GBA</italic> pathogenic variants have been identified in 5%-10% of individuals with PD [<xref ref-type="bibr" rid="gaucher.REF.sidransky.2009.1651">Sidransky et al 2009</xref>]. PD associated with mutation of <italic toggle="yes">GBA</italic> (GBA-PD) is clinically, pathologically, and pharmacologically indistinguishable from idiopathic &#x0201c;sporadic&#x0201d; PD, although GBA-PD has a slightly earlier onset (~5 years earlier) and more frequent cognitive dysfunction [<xref ref-type="bibr" rid="gaucher.REF.neumann.2009.1783">Neumann et al 2009</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="gaucher.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Saposin C deficiency or prosaposin deficiency.</bold> Saposin C is a cofactor for glucocerebrosidase in the hydrolysis of GL1. Saposin C is derived from proteolytic cleavage of prosaposin, which is encoded by a gene on chromosome 10q21-q22. Individuals with saposin C deficiency or prosaposin deficiency may present with symptoms characteristic of severe neuropathic Gaucher disease (GD) (i.e., progressive horizontal ophthalmoplegia, pyramidal and cerebellar signs, myoclonic jerks, and generalized seizures) [<xref ref-type="bibr" rid="gaucher.REF.p_mpols.1999.91">P&#x000e0;mpols et al 1999</xref>, <xref ref-type="bibr" rid="gaucher.REF.qi.2001.203">Qi &#x00026; Grabowski 2001</xref>] or non-neuronopathic disease [<xref ref-type="bibr" rid="gaucher.REF.tylkiszyma_ska.2007.538">Tylki-Szyma&#x00144;ska et al 2007</xref>]. These individuals demonstrate GL1 accumulation and visceromegaly but have normal glucocerebrosidase enzyme activity measured in vitro.</p>
        <p><bold>Lysosomal storage diseases (LSDs).</bold> Findings in GD may overlap with some lysosomal storage diseases; however, the distinctive clinical features associated with these lysosomal storage diseases, the availability of biochemical testing in clinical laboratories, and an understanding of their natural history should help distinguish between them.</p>
        <p><bold>Hepatosplenomegaly</bold> is observed in Niemann-Pick disease types A and B (see <related-object link-type="booklink" source-id="gene" document-id="npab" document-type="chapter">Acid Sphingomyelinase Deficiency</related-object>), <related-object link-type="booklink" source-id="gene" document-id="npc" document-type="chapter">Niemann-Pick disease type C</related-object>, <related-object link-type="booklink" source-id="gene" document-id="lal-def" document-type="chapter">Wolman disease</related-object>, the mucopolysaccharidoses (including <related-object link-type="booklink" source-id="gene" document-id="mps1" document-type="chapter">mucopolysaccharidosis type I</related-object> and <related-object link-type="booklink" source-id="gene" document-id="hunter" document-type="chapter">mucopolysaccharidosis type II</related-object>), and the oligosaccharidoses. The following features are not found in individuals with GD and should direct further investigations to these alternative diagnoses:</p>
        <list list-type="bullet">
          <list-item>
            <p>Coarse facial features</p>
          </list-item>
          <list-item>
            <p>Dysostosis multiplex on skeletal radiographs</p>
          </list-item>
          <list-item>
            <p>Vacuolated lymphocytes on peripheral blood smear examination</p>
          </list-item>
          <list-item>
            <p>The presence of a cherry-red spot on fundoscopy</p>
          </list-item>
          <list-item>
            <p>White matter changes (leukodystrophy) on brain MRI</p>
          </list-item>
        </list>
        <p><bold>Gaucher cells.</bold> The characteristic storage cells of GD should be distinguished from those found in other storage disorders such as Niemann-Pick disease type C. 'Pseudo Gaucher cells' which resemble Gaucher storage cells at the light microscopic but not ultrastructural level occur in a number of hematologic conditions including myeloproliferative and myelodysplastic disorders.</p>
        <p><bold>Legg-Calv&#x000e9;-Perthes disease.</bold> Osteonecrosis may be a presenting feature of GD, which should be considered in the differential diagnosis of children with suspected Legg-Calv&#x000e9;-Perthes disease [<xref ref-type="bibr" rid="gaucher.REF.kenet.2003.72">Kenet et al 2003</xref>].</p>
        <p><bold>Congenital ichthyoses and collodion skin changes</bold> are observed in <related-object link-type="booklink" source-id="gene" document-id="li-ar" document-type="chapter">autosomal recessive congenital ichthyosis</related-object>.</p>
        <p><bold>Hydrops fetalis</bold> may be encountered in other LSDs, including <related-object link-type="booklink" source-id="gene" document-id="gm1-ganglio" document-type="chapter">GM1 gangliosidosis</related-object>, sialidosis type 1, <related-object link-type="booklink" source-id="gene" document-id="lal-def" document-type="chapter">Wolman disease</related-object>, mucopolysaccharidosis type VII (MPS VII), mucopolysaccharidosis type IV (MPS IV; see <related-object link-type="booklink" source-id="gene" document-id="mps4a" document-type="chapter">MPS IVA</related-object>), galactosialidosis, <related-object link-type="booklink" source-id="gene" document-id="npc" document-type="chapter">Niemann-Pick disease type C</related-object>, disseminated lipogranulomatosis (Farber disease), infantile <related-object link-type="booklink" source-id="gene" document-id="issd" document-type="chapter">free sialic acid storage disease</related-object> (ISSD), and <related-object link-type="booklink" source-id="gene" document-id="ml2" document-type="chapter">mucolipidosis II</related-object> (I-cell disease) [<xref ref-type="bibr" rid="gaucher.REF.stone.1999.409">Stone &#x00026; Sidransky 1999</xref>].</p>
        <p><bold>Myoclonic seizures</bold> are also observed in <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">GM2 gangliosidosis</related-object>, sialidosis type 1, alpha-N-acetylgalactosaminidase deficiency, and fucosidosis. In addition to the LSDs, several genetic disorders are known to be associated with progressive myoclonic epilepsy [reviewed in <xref ref-type="bibr" rid="gaucher.REF.de_siqueira.2010.1612">de Siqueira 2010</xref>]. The lysosomal integral membrane protein-2 (LIMP-2) has been shown to facilitate lysosomal targeting for the nascent glucocerebrosidase [<xref ref-type="bibr" rid="gaucher.REF.reczek.2007.770">Reczek et al 2007</xref>]. Pathogenic variants in the gene encoding LIMP-2 have been associated with action myoclonus-renal failure [<xref ref-type="bibr" rid="gaucher.REF.guerrerol_pez.2012.1826">Guerrero-L&#x000f3;pez et al 2012</xref>].</p>
      </sec>
      <sec id="gaucher.Management_1">
        <title>Management</title>
        <sec id="gaucher.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>See <xref ref-type="sec" rid="gaucher.Surveillance">Surveillance</xref> for evaluations used to establish disease severity in an individual diagnosed with Gaucher disease (GD).</p>
          <p>Baseline (pre-treatment) assessments may be useful in selecting treatment modality and regimen (i.e., enzyme dose and frequency of infusion).</p>
          <p>Factors that may influence the extent of clinical testing at the time of diagnosis:</p>
          <list list-type="bullet">
            <list-item>
              <p>Age</p>
            </list-item>
            <list-item>
              <p>Mode of ascertainment (e.g., family screening vs disease signs and symptoms)</p>
            </list-item>
            <list-item>
              <p>Presence/absence of primary neurologic involvement</p>
            </list-item>
          </list>
        </sec>
        <sec id="gaucher.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management by a multidisciplinary team with expertise in treating GD is available at Comprehensive Gaucher Centers (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.gaucherdisease.org">National Gaucher Foundation</ext-link>).</p>
          <p>Although enzyme replacement therapy (ERT) has changed the natural history of GD and eliminated the need for splenectomy in individuals with hypersplenism, persons not receiving ERT and certain other individuals may require symptomatic treatment, including the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Partial or total splenectomy</bold> for individuals with massive splenomegaly with significant areas of infarction and persistent severe thrombocytopenia with high risk of bleeding</p>
            </list-item>
            <list-item>
              <p><bold>Transfusion of blood products</bold> for severe anemia and bleeding. Anemia and clotting problems unresponsive to ERT should prompt investigations for an intercurrent disease process. Evaluation by a hematologist is recommended prior to any major surgical or dental procedures or parturition [<xref ref-type="bibr" rid="gaucher.REF.hughes.2007.676">Hughes et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Analgesics for bone pain.</bold> Persistent bone pain in individuals receiving ERT should prompt evaluations to exclude the possibility of a mechanical problem (e.g., pathologic fracture or joint collapse secondary to osteonecrosis, degenerative arthritis).</p>
            </list-item>
            <list-item>
              <p><bold>Joint replacement surgery</bold> for relief from chronic pain and restoration of function (i.e., improved joint range of motion). Bone pain in individuals who have undergone joint replacement may indicate a problem with the prosthesis and the need for surgical revision.</p>
            </list-item>
            <list-item>
              <p><bold>Supplemental treatment.</bold> Oral bisphosphonates and calcium/vitamin D may benefit individuals with GD and low bone density [<xref ref-type="bibr" rid="gaucher.REF.wenstrup.2004.1253">Wenstrup et al 2004</xref>].</p>
            </list-item>
          </list>
          <p>Persons with GD with findings suggestive of multiple myeloma and parkinsonism should be referred to the appropriate specialists.</p>
        </sec>
        <sec id="gaucher.Prevention_of_Primary_Manifestat">
          <title>Prevention of Primary Manifestations</title>
          <p>
            <bold>Bone marrow transplantation (BMT)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Bone marrow transplantation (BMT) has been undertaken in individuals with severe GD, primarily those with chronic neurologic involvement (type 3 GD). Successful engraftment can correct the metabolic defect, improve blood counts, and reduce increased liver volume. In a few individuals, stabilization of neurologic and bone disease has occurred. However, the morbidity and mortality associated with BMT limit its use in individuals with type 1 and type 3 GD. Therefore, this procedure has been largely superseded by enzyme replacement therapy (see <bold>ERT</bold>).</p>
            </list-item>
            <list-item>
              <p>Individuals with chronic neurologic GD and progressive disease despite ERT may be candidates for BMT or a multi-modal approach (i.e., combined ERT and BMT).</p>
            </list-item>
          </list>
          <p><bold>Enzyme replacement therapy (ERT).</bold> ERT is based on the provision of sufficient exogenous enzyme to overcome the block in the catabolic pathway and effect the clearance of the stored substrate, GL1.</p>
          <list list-type="bullet">
            <list-item>
              <p>Global availability may differ, but there are three recombinant glucocerebrosidase enzyme preparations currently available. All are based on the human gene sequence, but are distinguished according to the cell type involved in their production: <bold>imiglucerase</bold> (Cerezyme<sup>&#x000ae;</sup>) generated in Chinese hamster ovary cells; <bold>velalglucerase alfa</bold> (VPRIV<sup>&#x000ae;</sup>) from human fibroblast-like cell line; and <bold>taliglucerase alfa</bold> (Elelyso<sup>&#x000ae;</sup>) from a carrot cell line. Each formulation is modified to expose the alpha-mannosyl (carbohydrate) residues for enhanced uptake by the macrophage.</p>
            </list-item>
            <list-item>
              <p>Regular intravenous infusions of the recombinant enzymes imiglucerase and velaglucerase have been demonstrated to be safe and effective in reversing those features resulting from hematologic and visceral (liver/spleen) involvement [<xref ref-type="bibr" rid="gaucher.REF.weinreb.2002.112">Weinreb et al 2002</xref>, <xref ref-type="bibr" rid="gaucher.REF.zimran.2010.4651">Zimran et al 2010</xref>]. Experience with taliglucerase alfa appears comparable [<xref ref-type="bibr" rid="gaucher.REF.zimran.2011.5767">Zimran et al 2011</xref>, <xref ref-type="bibr" rid="gaucher.REF.ben_turkia.2013.179">Ben Turkia et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>It is likely that end-stage histologic changes (e.g., fibrosis, infarction) influence the response to ERT. Thrombocytopenia may persist in individuals with residual splenomegaly and/or the presence of splenic nodules [<xref ref-type="bibr" rid="gaucher.REF.stein.2010.769">Stein et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>ERT is well tolerated. Approximately 10%-15% of individuals develop antibodies to infused imiglucerase; whereas antibody formation has been reported in 1% of persons receiving velaglucerase. In most cases these individuals remain asymptomatic [<xref ref-type="bibr" rid="gaucher.REF.rosenberg.1999.2081">Rosenberg et al 1999</xref>, <xref ref-type="bibr" rid="gaucher.REF.starzyk.2007.157">Starzyk et al 2007</xref>]. Adverse effects (e.g., pruritus, hives) are relatively well controlled with premedication using antihistamines.</p>
            </list-item>
            <list-item>
              <p><bold>Individuals with type 1 GD</bold> report improved health-related quality of life after 24-48 months of ERT [<xref ref-type="bibr" rid="gaucher.REF.damiano.1998.373">Damiano et al 1998</xref>, <xref ref-type="bibr" rid="gaucher.REF.masek.1999.263">Masek et al 1999</xref>, <xref ref-type="bibr" rid="gaucher.REF.weinreb.2007.576">Weinreb et al 2007</xref>]. After prolonged treatment, ERT reduces the rate of bone loss in a dose-dependent manner [<xref ref-type="bibr" rid="gaucher.REF.wenstrup.2007.119">Wenstrup et al 2007</xref>], improves bone pain, and reduces bone crises [<xref ref-type="bibr" rid="gaucher.REF.charrow.2007.205">Charrow et al 2007</xref>].The effectiveness of ERT for the treatment of neurologic disease remains to be established, although a few reports have suggested some benefit [<xref ref-type="bibr" rid="gaucher.REF.poll.2002.a25">Poll et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Individuals with type 2 GD</bold> and pyramidal tract signs are not likely to respond to ERT, perhaps because the underlying neuropathology is cell death rather than lysosomal storage of GL1 [<xref ref-type="bibr" rid="gaucher.REF.takahashi.1998.143">Takahashi et al 1998</xref>]. These individuals and those with hydrops fetalis are not appropriate candidates for BMT, ERT, or substrate reduction therapy (SRT) [<xref ref-type="bibr" rid="gaucher.REF.campbell.2003.629">Campbell et al 2003</xref>, <xref ref-type="bibr" rid="gaucher.REF.migita.2003.524">Migita et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Individuals with type 3 GD</bold> appear to derive some benefit from ERT, although long-term prognosis remains to be defined for this heterogeneous group [<xref ref-type="bibr" rid="gaucher.REF.vellodi.2001.319">Vellodi et al 2001</xref>]. Onset of progressive myoclonic seizures while on ERT appears to indicate a poor prognosis [<xref ref-type="bibr" rid="gaucher.REF.frei.2002.41">Frei &#x00026; Schiffmann 2002</xref>]. Brain stem auditory evoked responses have deteriorated in individuals with type 3 GD on ERT [<xref ref-type="bibr" rid="gaucher.REF.campbell.2003.629">Campbell et al 2003</xref>]. SRT used in combination with ERT for type 3 GD with progressive neurologic disease does not appear to alter ultimate prognosis.</p>
            </list-item>
          </list>
          <p>Consensus recommendations exist for ERT and monitoring of children with type 1 GD [<xref ref-type="bibr" rid="gaucher.REF.baldellou.2004">Baldellou et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.charrow.2004">Charrow et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.grabowski.2004">Grabowski et al 2004</xref>] (see <xref ref-type="sec" rid="gaucher.References">Published Guidelines/Consensus Statements</xref>). The optimal dose and frequency of recombinant enzyme administration is not certain, mostly because of limited information regarding tissue half-life and distribution and the limitations associated with the modalities used for assessing clinical disease course. Intravenously infused enzyme may not reach adequate concentrations in certain body sites (e.g., brain, bones, and lungs). In the majority of individuals, treatment is initiated with a dose of 15-60 units of enzyme per kg of body weight administered intravenously every two weeks. The enzyme dose may be increased or decreased after initiation of treatment and during the maintenance phase, based on response &#x02013; i.e., hematopoietic reconstitution, reduction of liver and spleen volumes, and stabilization or improvement in skeletal findings [<xref ref-type="bibr" rid="gaucher.REF.pastores.2004.4">Pastores et al 2004</xref>].</p>
          <p>Affected individuals may require assistance with insurance-related issues and reimbursement because of the high cost of ERT.</p>
          <p><bold>Substrate reduction therapy (SRT).</bold> SRT aims to restore metabolic homeostasis by limiting the amount of substrate precursor synthesized (and eventually subject to catabolism) to a level that can be effectively cleared by the mutant enzyme with residual hydrolytic activity [<xref ref-type="bibr" rid="gaucher.REF.dwek.2002.65">Dwek et al 2002</xref>]. A potential concern regarding the use of SRT is its nonspecificity; i.e., the substrate whose production is blocked or limited is a precursor in the formation of other glycosphingolipids (ganglio- and lacto- series).</p>
          <p><bold>Miglustat,</bold> the first oral agent for the treatment of individuals with mild to moderate Gaucher disease for whom ERT is not a therapeutic option (e.g., because of constraints such as allergy, hypersensitivity, or poor venous access). Miglustat has been approved in Canada, countries of the European Union, Israel, Switzerland, and the US. In at least three studies, involving more than 30 individuals with GD type 1, miglustat treatment resulted in a significant decrease in liver and spleen volume after six to 18 months, with clinical improvement noted over 24 months. Bone involvement and platelet and hemoglobin values remained stable or were modestly improved [<xref ref-type="bibr" rid="gaucher.REF.cox.2000.1481">Cox et al 2000</xref>, <xref ref-type="bibr" rid="gaucher.REF.elstein.2004a.757">Elstein et al 2004a</xref>, <xref ref-type="bibr" rid="gaucher.REF.pastores.2005.1215">Pastores et al 2005</xref>]. An increase in bone density at the lumbar spine and femoral neck was reported to occur as early as six months after the initiation of miglustat monotherapy [<xref ref-type="bibr" rid="gaucher.REF.pastores.2007.1645">Pastores et al 2007</xref>]. The most common adverse reactions noted in the clinical trials were weight loss (60% of individuals), and bloating, flatulence, and diarrhea (80%), which resolved or diminished with longer use of the product.</p>
          <p><bold>Eliglustat,</bold> an alternative inhibitor of glucosylceramide synthetase recently approved by the FDA, has been shown in clinical trials to be a safe and effective treatment for individuals with Gaucher disease type 1 who are not on any therapy as well as those previously treated with ERT.</p>
          <list list-type="bullet">
            <list-item>
              <p>In a placebo-controlled phase 3 study (ENGAGE) of patients not previously on any therapy, those who were given eliglustat for nine months showed a 28% decrease in spleen volume and a 7% decrease in liver volume as well as a 1.2 gm/dL increase in hemoglobin level and 42% increase in platelet count [<xref ref-type="bibr" rid="gaucher.REF.mistry.2015.695">Mistry et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>In a separate phase 3 study (ENGAGE) of patients previously on ERT, eliglustat demonstrated outcomes similar to imiglucerase for the composite primary endpoint of stability in spleen and liver volume, hemoglobin level, and platelet count from baseline to 12 months [<xref ref-type="bibr" rid="gaucher.REF.cox.2015">Cox et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>An effect on GD-related bone disease was suggested by a significant increase in lumbar spine T-scores (mean of -1.6 to -0.9) in 19 patients enrolled in the pivotal phase 2 study who were on eliglustat therapy for up to four years [<xref ref-type="bibr" rid="gaucher.REF.kamath.2014.1353">Kamath et al 2014</xref>].</p>
            </list-item>
          </list>
          <p>Note: (1) Reported side effects of eliglustat were generally mild. (2) The use of eliglustat requires cytochrome P450 2D6 genotyping and avoidance of drugs that may interact through this metabolic pathway. (3) Drug distribution studies indicate that eliglustat, a P-glycoprotein ligand, is not transported across the blood-brain barrier and, thus, not indicated for neuronopathic forms of GD. Preclinical studies involving analogs that may be efficacious for primary CNS involvement are ongoing [<xref ref-type="bibr" rid="gaucher.REF.larsen.2012.282">Larsen et al 2012</xref>].</p>
        </sec>
        <sec id="gaucher.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>The use of anticoagulants in individuals with severe thrombocytopenia and/or coagulopathy should be discussed with a hematologist to avoid the possibility of excessive bleeding.</p>
        </sec>
        <sec id="gaucher.Surveillance">
          <title>Surveillance</title>
          <p>Physicians who are the US regional coordinators for the International Collaborative Gaucher Group Registry (ICGG) and other groups have published recommendations for comprehensive serial monitoring of the severity and rate of disease progression [<xref ref-type="bibr" rid="gaucher.REF.baldellou.2004">Baldellou et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.charrow.2004">Charrow et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.grabowski.2004">Grabowski et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.vom_dahl.2006.1045">Vom Dahl et al 2006</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Medical history</bold> (at least every 6-12 months) including weight loss, fatigue, depression, change in social, domestic, or school- or work-related activities, bleeding from the nose or gums, menorrhagia, shortness of breath, abdominal pain, early satiety as a result of abdominal pressure, joint aches or reduced range of movement, and bone pain</p>
            </list-item>
            <list-item>
              <p><bold>Physical examination</bold> (at least every 6-12 months) including: heart and lungs, joint range of motion, gait, neurologic status, evidence of bleeding (bruises, petechiae). In children, attention should be given to growth (height, weight, and head circumference using standardized growth charts) and pubertal changes (using the Tanner staging system). Neurologic evaluation is particularly important in the early detection of type 2 and type 3 disease in children. A severity scoring tool has been developed to evaluate neurologic features of neuronopathic GD [<xref ref-type="bibr" rid="gaucher.REF.davies.2007.768">Davies et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Assessment of hemoglobin concentration and platelet count</bold> (with frequency based on symptoms and treatment status). Hemoglobin, platelet count, and coagulation indices should also be assessed prior to surgical or dental procedures.</p>
            </list-item>
            <list-item>
              <p><bold>Other blood tests</bold> at the physician's discretion may include measurement of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Serum concentrations of tartrate-resistant acid phosphatase, liver enzymes (aspartate aminotransferanse or alanine amino transferase), iron, ferritin, and vitamins B<sub>12</sub> and D.</p>
                </list-item>
                <list-item>
                  <p>Plasma activity of chitotriosidase, a macrophage-derived chitin-fragmenting hydrolase, and plasma concentration of PARC/CCL18. Levels are typically elevated, and are felt to correlate with body-wide burden of disease. An enzyme dose-dependent decrease in plasma chitotriosidase activity has been observed in affected individuals on ERT; however, up to 40% of affected individuals of European origin are homozygous or heterozygous for a common null variant, confounding interpretation of test results [<xref ref-type="bibr" rid="gaucher.REF.grace.2007.866">Grace et al 2007</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Assessment of spleen and liver volumes</bold> by MRI or volumetric computed tomography (CT). Parenchymal abnormalities can be identified as well. In situations in which access to an MRI or CT is problematic, abdominal ultrasonography (US) may be performed. Abdominal US may provide information on organ volume and parenchymal abnormalities and also call attention to the presence of gallstones [<xref ref-type="bibr" rid="gaucher.REF.patlas.2002.17">Patlas et al 2002</xref>]. MRI or US are the preferred modalities in the pediatric population.</p>
            </list-item>
            <list-item>
              <p><bold>Screening for pulmonary hypertension.</bold> EKG and echocardiography with Doppler studies to identify elevated pulmonary artery pressure</p>
            </list-item>
            <list-item>
              <p>
                <bold>Skeletal assessment</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Plain radiographs</bold> of the femur (anterior-posterior view), spine (lateral view), and any symptomatic sites. Radiographs can reflect the status of both the compact/mineralized compartment and medullary compartment. In children, particularly those with signs of growth and pubertal delay, x-ray of the left hand and wrist to determine bone age is appropriate.</p>
                </list-item>
                <list-item>
                  <p><bold>Coronal T<sub>1</sub>- and T<sub>2</sub>-weighted MR images of the hips to the distal femur.</bold> T<sub>1</sub>-weighted MRI is the most sensitive method for following bone marrow infiltration. T<sub>2</sub>-weighted MRI is the most sensitive method for detecting active bone infarcts, osteonecrosis, and osteomyelitis [<xref ref-type="bibr" rid="gaucher.REF.maas.2002b.a13">Maas et al 2002b</xref>]. The developmental transition from cellular (red) to fatty (yellow) bone marrow, which normally occurs from childhood to early adulthood, may confound interpretation of the extent of long bone infiltration by Gaucher cells (lipid-engorged macrophages) in affected children younger than age 15 years [<xref ref-type="bibr" rid="gaucher.REF.mchugh.2004.117">McHugh et al 2004</xref>]. Semiquantitative methods (BMB score and S-MRI score) have been developed to facilitate serial assessments [<xref ref-type="bibr" rid="gaucher.REF.robertson.2007.1521">Robertson et al 2007</xref>, <xref ref-type="bibr" rid="gaucher.REF.roca.2007.132">Roca et al 2007</xref>].</p>
                </list-item>
                <list-item>
                  <p><bold>Other methods</bold> include dual-energy x-ray absorptiometry (DEXA) to identify osteoporosis and risk for pathologic fractures, technetium Tc-99 sulfur colloid nuclear scanning to assess location and extent of infiltration [<xref ref-type="bibr" rid="gaucher.REF.mariani.2003.1253">Mariani et al 2003</xref>], and quantitative chemical-shift MRI or spectroscopy to quantify decrease in bone marrow fat content as a marker of bone marrow infiltration [<xref ref-type="bibr" rid="gaucher.REF.maas.2002a.961">Maas et al 2002a</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Assessment of disease severity.</bold> Two recent reports have delineated a means for scoring disease severity, incorporating standard assessments of disease severity [<xref ref-type="bibr" rid="gaucher.REF.di_rocco.2008.1211">Di Rocco et al 2008</xref>, <xref ref-type="bibr" rid="gaucher.REF.weinreb.2010.44">Weinreb et al 2010</xref>]. With increasing therapeutic options, the ability to benchmark response may inform the modality of choice and selected regimen [<xref ref-type="bibr" rid="gaucher.REF.weinreb.2008.890">Weinreb et al 2008</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="gaucher.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in individuals with moderate to severe thrombocytopenia.</p>
        </sec>
        <sec id="gaucher.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to offer testing to asymptomatic at-risk relatives so that those with glucocerebrosidase enzyme deficiency or two disease-causing alleles can benefit from early diagnosis and treatment to reduce morbidity.</p>
          <p>See <xref ref-type="sec" rid="gaucher.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gaucher.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancy may affect the course of GD both by exacerbating preexisting symptoms and by triggering new features such as bone pain. Women with severe thrombocytopenia and/or clotting abnormalities may have an increased risk of bleeding around the time of delivery [<xref ref-type="bibr" rid="gaucher.REF.elstein.2004b.435">Elstein et al 2004b</xref>].</p>
        </sec>
        <sec id="gaucher.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Chaperone-mediated enzyme enhancement therapy.</bold> Pharmacologic chaperones, competitive reversible active site inhibitors, serve as a folding template for the defective enzyme during its transit to the ER. Such agents may restore enzyme activity within the lysosome and clear stored substrate. The drug isofagamine, which has been shown to exhibit these properties in studies of cultured fibroblasts in vitro, is currently in clinical trials to establish its safety and efficacy when given to adults with type 1 GD [<xref ref-type="bibr" rid="gaucher.REF.steet.2007.1376">Steet et al 2007</xref>].</p>
          <p>Ambroxol, a mucolytic agent, is also a potential pharmacologic GBA chaperone [<xref ref-type="bibr" rid="gaucher.REF.zimran.2013.134">Zimran et al 2013</xref>].</p>
          <p>Histone deacetylase inhibitors increase the quantity and activity of glucocerebrosidase by limiting the deacetylation of heat shock protein 90. As a consequence, there is less enzyme degradation [<xref ref-type="bibr" rid="gaucher.REF.yang.2013.966">Yang et al 2013</xref>].</p>
          <p><bold>Gene therapy.</bold> Gene therapy involves the introduction of <italic toggle="yes">GBA</italic> into hematopoietic stem cells [<xref ref-type="bibr" rid="gaucher.REF.enquist.2006.13819">Enquist et al 2006</xref>]. In limited trials, some enzyme has been produced by transduced cells, but enzyme production does not appear to be sustained and therefore does not result in a permanent cure. It is anticipated that transduced cells would not have a proliferative advantage over uncorrected cells. Furthermore, it is unlikely that significant metabolic cross-correction would occur as only small amounts of enzyme are secreted into the circulation.</p>
          <p>In a murine model of GD (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">D409V</xref>/null) intravenous administration of a recombinant AAV8 serotype vector bearing human glucocerebrosidase resulted in sustained hepatic enzyme secretion, preventing GL-1 accumulation in presymptomatic mice and normalizing GL-1 levels in older mice [<xref ref-type="bibr" rid="gaucher.REF.mceachern.2006.719">McEachern et al 2006</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="gaucher.Other">
          <title>Other</title>
          <p>The elevation of the serum concentration of several serologic markers (e.g., D-dimer, CCL18/PARC, CD163) in persons with GD is considered a possible surrogate indicator of disease burden that could be used in monitoring treatment response [<xref ref-type="bibr" rid="gaucher.REF.shitrit.2003.236">Shitrit et al 2003</xref>, <xref ref-type="bibr" rid="gaucher.REF.boot.2004.33">Boot et al 2004</xref>, <xref ref-type="bibr" rid="gaucher.REF.m_ller.2004.135">M&#x000f8;ller et al 2004</xref>]. However, the prognostic value of these markers, their role in patient stratification according to clinical disease severity, and/or determination of the optimum time to initiate therapy are unknown.</p>
        </sec>
      </sec>
      <sec id="gaucher.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gaucher.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Gaucher disease (GD) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="gaucher.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In most instances, the parents of a proband are heterozygotes and thus carry a single copy of a pathogenic variant in <italic toggle="yes">GBA</italic>.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
            <list-item>
              <p>Because the carrier frequency for GD in certain populations is high (e.g., 1:18 in individuals of Ashkenazi Jewish heritage) and the <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S/N370S</xref> phenotype is variable, it is possible that a parent may be found to be homozygous rather than heterozygous.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of a proband are obligate heterozygotes.</p>
            </list-item>
            <list-item>
              <p>A high carrier rate for GD exists in certain populations, increasing the risk that an affected individual may have a reproductive partner who is heterozygous. In the Ashkenazi Jewish population, for example, one in 18 individuals is a carrier for GD; the offspring of such an individual and a proband are at 50% risk of being affected and 50% risk of being obligate heterozygotes.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of an obligate heterozygote is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="gaucher.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Biochemical genetic testing</bold>. Measurement of glucocerebrosidase enzyme activity in peripheral blood leukocytes is unreliable for carrier determination because of significant overlap in residual enzyme activity levels between obligate carriers and the general (non-carrier) population.</p>
          <p><bold>Molecular genetic testing</bold> can be used to identify carriers among at-risk family members once the pathogenic variants have been identified in the family.</p>
          <p>Testing for the four common <italic toggle="yes">GBA</italic> alleles (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">N370S</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">L444P</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">84GG</xref>, <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">IVS2+1</xref>) has been included in panels specifically designed for carrier screening in the Ashkenazi Jewish population [<xref ref-type="bibr" rid="gaucher.REF.zuckerman.2007.1281">Zuckerman et al 2007</xref>].</p>
          <p>Because the frequency for GD in certain populations is high (e.g., individuals of Ashkenazi Jewish heritage) and the N370S/N370S phenotype is variable, individuals who undergo carrier testing may be identified as being homozygous.</p>
          <p>Pre-conception testing of the partner of a known carrier or affected individual may be requested, especially in ethnic groups of high prevalence. In this instance targeted analysis for pathogenic variants is insufficient and full sequence analysis should be undertaken.</p>
        </sec>
        <sec id="gaucher.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="gaucher.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="gaucher.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic variants have been identified in a family member, prenatal testing for pregnancies at increased risk is possible either through a clinical laboratory or a laboratory offering custom prenatal testing.</p>
          <p>Except in families in which a previously affected sibling had neurologic disease (i.e., types 2 or 3), it is not possible to be certain of the phenotypic severity in a pregnancy at risk. Individuals with GD with acute neurologic disease (i.e., type 2) tend to have a similar disease course. However, it should be noted that individuals with GD and chronic neurologic involvement (i.e., type 3) could show variable rates of disease progression, even when they are members of the same family.</p>
          <p>Requests for prenatal testing for treatable conditions such as GD type 1 are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate [<xref ref-type="bibr" rid="gaucher.REF.beutler.2007.1329">Beutler 2007</xref>, <xref ref-type="bibr" rid="gaucher.REF.zuckerman.2007.1281">Zuckerman et al 2007</xref>].</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="gaucher.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gaucher.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="gaucher.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Gaucher disease (GD) is caused by deficient activity of the lysosomal enzyme glucocerebrosidase and the resultant accumulation of its undegraded substrate, glucosylceramide (GL1) and other glycolipids. The major peripheral substrate source is the breakdown of senescent blood cells and tissue debris; the incompletely metabolized GL1 substrate is stored in cells of monocyte/macrophage lineage of the reticuloendothelial system. In the CNS, GL1 is believed to originate from the turnover of membrane gangliosides, although neuronal cell death may be the basis of neuropathic involvement [<xref ref-type="bibr" rid="gaucher.REF.aerts.2003.905">Aerts et al 2003</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">GBA</italic>, the glucosidase, beta, acid gene, comprises 7 kb with 11 exons; the cDNA is approximately 2.5 kb. Two different upstream ATG codons are utilized as translation initiation sites. A highly homologous (96% identity) pseudogene (5 kb) is located 16 kb downstream. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gaucher" object-id="gaucher.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> Several sequence alterations that are not believed to have a primary role in disease causation have been found [<xref ref-type="bibr" rid="gaucher.REF.d_azfont.2003.426">D&#x000ed;az-Font et al 2003</xref>, <xref ref-type="bibr" rid="gaucher.REF.tayebi.2003a.519">Tayebi et al 2003a</xref>, <xref ref-type="bibr" rid="gaucher.REF.montfort.2004.567">Montfort et al 2004</xref>]. The extent to which these variants may influence the phenotype or clinical disease expression remains to be established.</p>
          <p>Note: A related gene, <italic toggle="yes">GBA2</italic> (glucosidase beta (bile acid) 2), encodes a microsomal nonlysosomal glucosylceramidase that catalyzes the conversion of glucosylceramide to free glucose and ceramide and the hydrolysis of bile acid 3-O-glucosides. Pathogenic variants of <italic toggle="yes">GBA2</italic> have been shown to cause an autosomal recessive (AR) form of cerebellar ataxia with spasticity [<xref ref-type="bibr" rid="gaucher.REF.hammer.2013.245">Hammer et al 2013</xref>] and AR hereditary spastic paraplegia 46 (HSP46) [<xref ref-type="bibr" rid="gaucher.REF.martin.2013.238">Martin et al 2013</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> The abnormal alleles include missense and nonsense variants, splice junction variants, deletions and insertions of one or more nucleotides, and complex alleles resulting from gene conversion or recombination with the downstream pseudogene (see <related-object source-id="gene" document-id="gaucher" object-id="gaucher.molgen.TA">Table A</related-object>) [<xref ref-type="bibr" rid="gaucher.REF.rozenberg.2006.204">Rozenberg et al 2006</xref>, <xref ref-type="bibr" rid="gaucher.REF.alfonso.2007.391">Alfonso et al 2007</xref>]. At least 200 pathogenic variants in <italic toggle="yes">GBA</italic> have been identified. Historically, <italic toggle="yes">GBA</italic> variants were numbered based on the position in the nucleotide sequence that encodes the mature glucocerebrosidase protein, wherein the first nucleotide of the alanine codon (GCC) was designated as 1. This naming convention continues to be used (see <related-object source-id="gene" document-id="gaucher" object-id="gaucher.molgen.TA">Table A</related-object>), although it does not comply with current standards of nomenclature (<xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">Table 5</xref>).</p>
          <p>The variants N370S, 84GG, IVS2+1G&#x0003e;A, and L444P account for 90% of the mutant alleles in Ashkenazi Jewish individuals with type 1 GD and for 50%-60% of mutant alleles in non-Jewish individuals with type 1 GD. The frequencies of the most common genotypes associated with the N370S allele are listed in <xref ref-type="table" rid="gaucher.T.frequency_of_genotypes_involvi">Table 4</xref>. The frequency of the N370S allele is higher among Iberians (Portuguese: 63%; Spanish: 46%) than among other non-Jewish population groups from Western, Central, and Eastern Europe [<xref ref-type="bibr" rid="gaucher.REF.giraldo.2000.792">Giraldo et al 2000</xref>, <xref ref-type="bibr" rid="gaucher.REF.alfonso.2007.391">Alfonso et al 2007</xref>]. On the other hand, the N370S and 84GG alleles have not been identified among Japanese and Chinese individuals with GD. The occurrence of deleterious alleles among the Japanese (e.g., L444P: 41% allele frequency; <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">F213I</xref>: 14%) and Chinese (L444P: 54%; <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">RecNciI</xref>: 25%) may explain the higher incidence of neuropathic disease in these populations [<xref ref-type="bibr" rid="gaucher.REF.wan.2006.422">Wan et al 2006</xref>]. Thus, screening restricted to the four 'common' pathogenic variants (N370S, 84GG, IVS2+1G&#x0003e;A, and L444P) does not lead to 100% detection.</p>
          <table-wrap id="gaucher.T.frequency_of_genotypes_involvi" position="anchor" orientation="portrait">
            <label>Table 4. </label>
            <caption>
              <p>Frequency of Genotypes Involving at Least One Copy of N370S</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Genotype&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Ashkenazi Jewish Individuals&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Non-Jewish Individuals&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/N370S</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">41%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">9%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/L444P</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">19%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/84-85insG</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">23%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">0%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/IVS2+1G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/V394L</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">0%</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S/RecNciI&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0%</td>
                  <td headers="hd_h_gaucher.T.frequency_of_genotypes_involvi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Table does not include all possible genotype permutations and thus frequency figures do not account for 100% of individuals.</p>
              </fn>
              <fn id="gaucher.TF.4.1">
                <label>1. </label>
                <p><xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">Table 5</xref> provides the variant name and nucleotide changes according to current nomenclature guidelines.</p>
              </fn>
              <fn id="gaucher.TF.4.2">
                <label>2. </label>
                <p>Data derived from <xref ref-type="bibr" rid="gaucher.REF.koprivica.2000.1777">Koprivica et al [2000]</xref>. In this paper, the R463C variant was identified in nine (14%) of the non-Jewish individuals with type 1 GD, but in only one Ashkenazi Jewish individual with type 1 GD (L444P/R463C). The 55-bp deletion was found in two non-Jewish individuals with type 1 GD (both N370S/del 55bp) and one non-Jewish individual with type 3 GD in whom the second allele remains to be identified.</p>
              </fn>
              <fn id="gaucher.TF.4.3">
                <label>3. </label>
                <p>Data derived from <xref ref-type="bibr" rid="gaucher.REF.filocamo.2002.234">Filocamo et al [2002]</xref>, a study involving 144 unrelated Italian individuals with GD. This study represents the largest single group of non-Jewish individuals examined, with information on genotype rather than individual disease allele frequency.</p>
              </fn>
              <fn id="gaucher.TF.4.4">
                <label>4. </label>
                <p>Recombinant allele; see <xref ref-type="table" rid="gaucher.T.selected_gba_pathogenic_alleli">Table 5</xref>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <table-wrap id="gaucher.T.selected_gba_pathogenic_alleli" position="anchor" orientation="portrait">
            <label>Table 5. </label>
            <caption>
              <p>Selected <italic toggle="yes">GBA</italic> Pathogenic Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Common Variant Name&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change per HGVS Nomenclature</th>
                  <th id="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">IVS2+1G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.115+1G&#x0003e;A&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_4" rowspan="21" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000157.3">NM_000157.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000148.2">NP_000148.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">84GG (84-85insG)</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.84dupG&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu29AlafsTer18</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R120Q</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.476G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg159Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R120W</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.475C&#x0003e;T</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg159Trp</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R131L</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.509G&#x0003e;T</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg170Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N188S</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.680A&#x0003e;G</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn227Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">S196P</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.703T&#x0003e;C</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ser235Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">F213I</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.754T&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe252Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">H255Q</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.882T&#x0003e;G</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.His294Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R257Q</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.887G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg296Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">G377S</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1246G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly416Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">N370S</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1226A&#x0003e;G</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn409Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">L444P</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1448T&#x0003e;C</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu483Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">55bp del exon 9</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1263del55</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">V394L</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1297G&#x0003e;T</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val433Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">D409H</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1342G&#x0003e;C</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp448His</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">D409V</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1343A&#x0003e;T</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp448Val</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R463C</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1504C&#x0003e;T</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg502Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R463H</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1505G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg502His</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">R496H</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1604G&#x0003e;A</td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg535His</td>
                </tr>
                <tr>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">RecNciI&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_2 hd_h_gaucher.T.selected_gba_pathogenic_alleli_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">(complex allele involving several changes at a specific location)&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="gaucher.TF.5.1">
                <label>1.&#x000a0;</label>
                <p>The common variant names are used in this <italic toggle="yes">GeneReview</italic>. In these instances, amino acid number 1 is the first residue (Ala) of the mature protein. In contrast, the standard naming convention designates amino acid number 1 as the first residue (Met) of the signal sequence.</p>
              </fn>
              <fn id="gaucher.TF.5.2">
                <label>2. </label>
                <p>Variants in the signal sequence</p>
              </fn>
              <fn id="gaucher.TF.5.3">
                <label>3. </label>
                <p>Recombinant allele derived from a recombination between functional <italic toggle="yes">GBA</italic> and pseudogene <italic toggle="yes">GBAP1</italic>; see also <xref ref-type="table" rid="gaucher.T.proportion_of_individuals_with">Table 2</xref> [<xref ref-type="bibr" rid="gaucher.REF.eyal.1990.277">Eyal et al 1990</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> Glucocerebrosidase (also known as glucosylceramidase) is a lysosomal membrane-associated glycoprotein. The mature protein is composed of 497 amino acids, with four oligosaccharide chains coupled to specific asparagine residues [<xref ref-type="bibr" rid="gaucher.REF.van_weely.2000.11">van Weely &#x00026; Aerts 2000</xref>]. The three-dimensional conformation of the enzyme is stabilized by the formation of three disulfide bonds. The enzyme is responsible for hydrolyzing glucosylceramide into glucose and ceramide.</p>
          <p>Glucocerebrosidase enzyme activity is stimulated by interaction with the lipid phospatidylserine and the protein saposin C. Structural predictions (based on hydrophobic cluster analysis) indicate that the glutamine residues 235 and 340 play key roles in the active site of human glucocerebrosidase [<xref ref-type="bibr" rid="gaucher.REF.fabrega.2002.151">Fabrega et al 2002</xref>]. The nascent glucocerebrosidase polypeptide is composed of 536 amino acids, including 39 that encode a signal sequence that is later cleaved after it directs the polypeptide to transit the endoplasmic reticulum. Two different upstream ATG codons are utilized as translation initiation sites; use of the second ATG translation start leaves a functional signal sequence of 19 amino acid residues. The 497-amino acid sequence of the mature protein is the same regardless of the translation start codon.</p>
          <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">GBA</italic> pathogenic variants result in mRNA instability, and/or a severely truncated protein, or an enzyme with altered activity and/or conformation [<xref ref-type="bibr" rid="gaucher.REF.grabowski.1997.635">Grabowski &#x00026; Horowitz 1997</xref>].</p>
        </sec>
      </sec>
      <sec id="gaucher.References">
        <title>References</title>
        <sec id="gaucher.Published_GuidelinesConsensus_St">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="gaucher.Published_GuidelinesConsensus_St.reflist0">
            <ref id="gaucher.REF.baldellou.2004">
              <mixed-citation publication-type="webpage">Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, Harris CM, Kaplan P, McHugh K, Mengel E, Vellodi A. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. 2004. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.springerlink.com/content/ejp8dkkajpt28571/fulltext.html">online</ext-link>. Accessed 8-6-15.</mixed-citation>
            </ref>
            <ref id="gaucher.REF.charrow.2004">
              <mixed-citation publication-type="webpage">Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. 2004. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S002234760300814X">online</ext-link>. Accessed 8-6-15.</mixed-citation>
            </ref>
            <ref id="gaucher.REF.grabowski.2004">
              <mixed-citation publication-type="webpage">Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. 2004. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.springerlink.com/content/69j641ajgd5um94v/fulltext.pdf">online</ext-link>. Accessed 8-6-15.</mixed-citation>
            </ref>
            <ref id="gaucher.REF.nih_technology_assessment_panel_on_gaucher_disease.1996.548">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>NIH Technology Assessment Panel on Gaucher Disease</collab>
                </person-group>
                <article-title>Gaucher disease. Current issues in diagnosis and treatment.</article-title>
                <source>JAMA</source>
                <year>1996</year>
                <volume>275</volume>
                <fpage>548</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">8606477</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gaucher.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gaucher.Literature_Cited.reflist0">
            <ref id="gaucher.REF.aerts.2003.905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boot</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention.</article-title>
                <source>Philos Trans R Soc Lond B Biol Sci</source>
                <volume>358</volume>
                <fpage>905</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">12803924</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.alfonso.2007.391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alfonso</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aznarez</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giralt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocovi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain.</article-title>
                <source>J Hum Genet</source>
                <volume>52</volume>
                <fpage>391</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17427031</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.azuri.1998.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Azuri</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lahad</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrahamov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadas-Halpern</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Asymptomatic Gaucher disease implications for large-scale screening.</article-title>
                <source>Genet Test</source>
                <volume>2</volume>
                <fpage>297</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10464607</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.baldellou.2004.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baldellou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McHugh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.</article-title>
                <source>Eur J Pediatr</source>
                <volume>163</volume>
                <fpage>67</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">14677062</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.ben_turkia.2013.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ben Turkia</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukina</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kisinovsky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bavdekar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Dridi</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sureshkumar</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crombez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhirangi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.</article-title>
                <source>Am J Hematol.</source>
                <volume>88</volume>
                <fpage>179</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">23400823</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.beutler.2006.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Gaucher disease: multiple lessons from a single gene disorder.</article-title>
                <source>Acta Paediatr Suppl.</source>
                <volume>95</volume>
                <fpage>103</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16720474</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.beutler.2007.1329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Carrier screening for Gaucher disease: more harm than good?</article-title>
                <source>JAMA</source>
                <volume>298</volume>
                <fpage>1329</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">17878426</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.beutler.2004.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease.</article-title>
                <source>J Lab Clin Med</source>
                <volume>144</volume>
                <fpage>65</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15322500</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.beutler.1994.212">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelbart</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Erroneous assignment of Gaucher disease genotype as a consequence of a complete gene deletion.</article-title>
                <source>Hum Mutat.</source>
                <year>1994</year>
                <volume>4</volume>
                <fpage>212</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">7833951</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.beutler.2002.986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Polymorphisms in glucosylceramide (glucocerebroside) synthase and the Gaucher disease phenotype.</article-title>
                <source>Isr Med Assoc J</source>
                <volume>4</volume>
                <fpage>986</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12489486</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.biegstraaten.2011.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biegstraaten</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Schaik</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langeveld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannens</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bour</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgibbon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A monozygotic twin pair with highly discordant Gaucher phenotypes.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <volume>46</volume>
                <fpage>39</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">21056933</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.bohlega.2000.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bohlega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kambouris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahid</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Homsi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Sous</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC).</article-title>
                <source>Neurology</source>
                <volume>54</volume>
                <fpage>261</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10636167</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.boot.2004.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boot</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleijlevens</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Breemen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Meurs</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boven</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.</article-title>
                <source>Blood</source>
                <volume>103</volume>
                <fpage>33</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12969956</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.boven.2004.359">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boven</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Meurs</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boot</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laman</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.</article-title>
                <source>Am J Clin Pathol.</source>
                <volume>122</volume>
                <fpage>359</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">15362365</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.brautbar.2004.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brautbar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pines</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrahamov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Effect of enzyme replacement therapy on gammopathies in Gaucher disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>32</volume>
                <fpage>214</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14757437</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.bultron.2010.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bultron</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kacena</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boxer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sathe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The risk of Parkinson&#x02019;s disease in type 1 Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>33</volume>
                <fpage>167</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">20177787</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.campbell.2003.629">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirimanna</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>A model of neuronopathic Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>26</volume>
                <fpage>629</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">14707511</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.capablo.2008.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Capablo</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saenz de Cabez&#x000f3;n</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraile</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alfonso</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocovi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <collab>Spanish Group on Gaucher Disease</collab>
                </person-group>
                <year>2008</year>
                <article-title>Neurological evaluation of patients with Gaucher disease diagnosed as type 1.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <volume>79</volume>
                <fpage>219</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17682016</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.charrow.2004.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prakash-Cheng</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wappner</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.</article-title>
                <source>J Pediatr</source>
                <volume>144</volume>
                <fpage>112</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">14722528</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.charrow.2007.205">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dulisse</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.</article-title>
                <source>Clin Genet</source>
                <volume>71</volume>
                <fpage>205</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">17309642</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.ciana.2003.185">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ciana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leopaldi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamaro</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katouzian</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronfani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Bone marker alterations in patients with type 1 Gaucher disease.</article-title>
                <source>Calcif Tissue Int.</source>
                <volume>72</volume>
                <fpage>185</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12522660</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.cohen.2003.838">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Bone crises in Gaucher disease.</article-title>
                <source>Isr Med Assoc J</source>
                <volume>5</volume>
                <fpage>838</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14650121</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.cox.2000.1481">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Weely</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hrebicek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butters</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwek</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moyses</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gow</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.</article-title>
                <source>Lancet</source>
                <volume>355</volume>
                <fpage>1481</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10801168</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.cox.2015">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drelichman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cravo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balwani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burrow</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puga</surname>
                    <given-names>AC</given-names>
                  </name>
                </person-group>
                <article-title>Eliglustat versus imiglucerase in patients with Gaucher&#x02019;s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.</article-title>
                <source>Lancet</source>
                <year>2015</year>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.cozar.2011.226">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cozar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dominissini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zampieri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilageliu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grinberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dardis</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Molecular characterization of a new deletion of the GBA1 gene due to an inter Alu recombination event.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2011</year>
                <volume>102</volume>
                <fpage>226</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21036086</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.damiano.1998.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Damiano</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ware</surname>
                    <given-names>JE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.</article-title>
                <source>Qual Life Res</source>
                <volume>7</volume>
                <fpage>373</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">9691718</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.davies.2007.768">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surtees</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeVile</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoon</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>768</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17876722</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.de_fost.2006.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vom Dahl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weverling</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brill</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brett</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haussinger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Increased incidence of cancer in adult Gaucher disease in Western Europe.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>36</volume>
                <fpage>53</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16246599</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.de_siqueira.2010.1612">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Siqueira</surname>
                    <given-names>LF</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.</article-title>
                <source>J Neurol.</source>
                <volume>257</volume>
                <fpage>1612</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20593193</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.deghady.2006.411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deghady</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marzouk</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Shayeb</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wali</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Coagulation abnormalities in type 1 Gaucher disease in children.</article-title>
                <source>Pediatr Hematol Oncol</source>
                <volume>23</volume>
                <fpage>411</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16728361</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.di_rocco.2008.1211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giona</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carubbi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minichilli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellini</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.</article-title>
                <source>Haematologica.</source>
                <volume>93</volume>
                <fpage>1211</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18603565</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.d_azfont.2003.426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x000ed;az-Font</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormand</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chamoles</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grinberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilageliu</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Gene rearrangements in the glucocerebrosidase-metaxin region giving rise to disease-causing mutations and polymorphisms. Analysis of 25 Rec NciI alleles in Gaucher disease patients.</article-title>
                <source>Hum Genet</source>
                <volume>112</volume>
                <fpage>426</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12589426</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.drugan.2002.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Drugan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jebeleanu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigorescu-Sido</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craciun</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>28</volume>
                <fpage>13</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">11814307</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.dwek.2002.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dwek</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butters</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zitzmann</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Targeting glycosylation as a therapeutic approach.</article-title>
                <source>Nat Rev Drug Discov</source>
                <volume>1</volume>
                <fpage>65</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">12119611</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.elstein.2004a.757">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Weely</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hrebicek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platt</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butters</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwek</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004a</year>
                <article-title>Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>27</volume>
                <fpage>757</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">15505381</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.elstein.2004b.435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eisenberg</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Granovsky-Grisaru</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabinowitz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samueloff</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2004b</year>
                <article-title>Pregnancies in Gaucher disease: a 5-year study.</article-title>
                <source>Am J Obstet Gynecol</source>
                <volume>190</volume>
                <fpage>435</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">14981386</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.enquist.2006.13819">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Enquist</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilsson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ooka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansson</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ehinger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karlsson</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Effective cell and gene therapy in a murine model of Gaucher disease.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>103</volume>
                <fpage>13819</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">16954197</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.eyal.1990.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eyal</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilder</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horowitz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Prevalent and rare mutations among Gaucher patients.</article-title>
                <source>Gene</source>
                <volume>96</volume>
                <fpage>277</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">2269438</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.fabrega.2002.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fabrega</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durand</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mornon</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehn</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The active site of human glucocerebrosidase: structural predictions and experimental validations</article-title>
                <source>J Soc Biol</source>
                <volume>196</volume>
                <fpage>151</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">12360744</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.felderhoffmueser.2004.138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Felderhoff-Mueser</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uhl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penzel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Landeghem</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obladen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopitz</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Intrauterine onset of acute neuropathic type 2 Gaucher disease: identification of a novel insertion sequence.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>128A</volume>
                <fpage>138</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">15214004</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.filocamo.2002.234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzotti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stroppiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giona</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Regis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corsolini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoboli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatti</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian Gaucher patients.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>234</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12204005</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.frei.2002.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frei</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Myoclonus in Gaucher disease.</article-title>
                <source>Adv Neurol</source>
                <volume>89</volume>
                <fpage>41</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11968465</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.george.2001.360">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMahon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lytle</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichtin</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation.</article-title>
                <source>Clin Genet</source>
                <volume>59</volume>
                <fpage>360</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11359469</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.giraldo.2000.792">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocovi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Calvo</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio-Felix</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giralt</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>On the behalf of Spanish Gaucher's Disease Registry Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.</article-title>
                <source>Haematologica</source>
                <volume>85</volume>
                <fpage>792</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10942924</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.gokeralpan.2003.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goker-Alpan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3.</article-title>
                <source>J Pediatr</source>
                <volume>143</volume>
                <fpage>273</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12970647</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.gokeralpan.2010.641">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goker-Alpan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giasson</surname>
                    <given-names>BI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Glucocerebrosidase is present in &#x003b1;-synuclein inclusions in Lewy body disorders.</article-title>
                <source>Acta Neuropathol.</source>
                <volume>120</volume>
                <fpage>641</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20838799</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.grabowski.2004.58">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldellou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocovi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.</article-title>
                <source>Eur J Pediatr</source>
                <volume>163</volume>
                <fpage>58</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">14677061</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.grabowski.1997.635">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horowitz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Gaucher's disease: molecular, genetic and enzymological aspects.</article-title>
                <source>Baillieres Clin Haematol</source>
                <volume>10</volume>
                <fpage>635</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">9497856</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.grace.2007.866">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balwani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nazarenko</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prakash-Cheng</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring.</article-title>
                <source>Hum Mutat</source>
                <volume>28</volume>
                <fpage>866</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">17464953</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.guerrerol_pez.2012.1826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guerrero-L&#x000f3;pez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Ruiz</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gir&#x000e1;ldez</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dur&#x000e1;n-Herrera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Querol-Pascual</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ram&#x000ed;rez-Moreno</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e1;s</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratosa</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>A new SCARB2 mutation in a patient with progressive myoclonus ataxia without renal failure.</article-title>
                <source>Mov Disord.</source>
                <volume>27</volume>
                <fpage>1826</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23225201</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.halperin.2006.426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Halperin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>36</volume>
                <fpage>426</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16651014</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.halperin.2007.275">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Halperin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?</article-title>
                <source>Acta Neurol Scand</source>
                <volume>115</volume>
                <fpage>275</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17376127</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.hammer.2013.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hammer</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eleuch-Fayache</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schottlaender</surname>
                    <given-names>LV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nehdi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbs</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arepalli</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hernandez</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sailer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cai</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shrader</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sassi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouhlal</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amouri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>92</volume>
                <fpage>245</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">23332917</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.harris.1999.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Ocular motor abnormalities in Gaucher disease.</article-title>
                <source>Neuropediatrics</source>
                <volume>30</volume>
                <fpage>289</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10706022</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.hughes.2007.676">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellini</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Droogenbroeck</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marinakis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villarubia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhukovskaya</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.</article-title>
                <source>Br J Haematol</source>
                <volume>138</volume>
                <fpage>676</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">17655728</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.inui.2001.137">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otani</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakayama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules.</article-title>
                <source>J Pediatr</source>
                <volume>138</volume>
                <fpage>137</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11148530</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.kamath.2014.1353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamath</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dragosky</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arreguin</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguzzi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puga</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norfleet</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterschmitt</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenthal</surname>
                    <given-names>DI</given-names>
                  </name>
                </person-group>
                <article-title>Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.</article-title>
                <source>Skeletal Radiol.</source>
                <year>2014</year>
                <volume>43</volume>
                <fpage>1353</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">24816856</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.kenet.2003.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kenet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mor</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubetsky</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mosheiff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itzchaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>31</volume>
                <fpage>72</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12850487</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.koprivica.2000.1777">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koprivica</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frisch</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Analysis and classification of 304 mutant alleles in patients with Type 1 and Type 3 Gaucher disease.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>1777</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">10796875</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.lachmann.2004.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>IR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halsall</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Twin pairs showing discordance of phenotype in adult Gaucher's disease.</article-title>
                <source>QJM</source>
                <volume>97</volume>
                <fpage>199</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">15028849</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.lalazar.2006.1249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lalazar</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preston</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zigmond</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Yaacov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilan</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Glycolipids as immune modulatory tools.</article-title>
                <source>Mini Rev Med Chem</source>
                <volume>6</volume>
                <fpage>1249</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">17100636</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.landgren.2007.1189">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Landgren</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turesson</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gridley</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caporaso</surname>
                    <given-names>NE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease.</article-title>
                <source>Arch Intern Med</source>
                <volume>167</volume>
                <fpage>1189</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">17563029</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.langeveld.2008.428">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langeveld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauerwein</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <volume>40</volume>
                <fpage>428</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">17950007</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.langeveld.2007a.985">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langeveld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiersinga</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2007a</year>
                <article-title>Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>985</fpage>
                <pub-id pub-id-type="pmid">17912612</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.langeveld.2007b.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langeveld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheij</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubbelhuis</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauerwein</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simons</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia.</article-title>
                <source>Metabolism</source>
                <volume>56</volume>
                <fpage>314</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17292718</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.larsen.2012.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Larsen</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirchhoff</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Showalter</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keep</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shayman</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.</article-title>
                <source>J Lipid Res.</source>
                <year>2012</year>
                <volume>53</volume>
                <fpage>282</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">22058426</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.maas.2002a.961">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akkerman</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Den Heeten</surname>
                    <given-names>GJ</given-names>
                  </name>
                </person-group>
                <year>2002a</year>
                <article-title>Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.</article-title>
                <source>AJR Am J Roentgenol</source>
                <volume>179</volume>
                <fpage>961</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12239046</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.maas.2002b.a13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terk</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <year>2002b</year>
                <article-title>Imaging and quantifying skeletal involvement in Gaucher disease.</article-title>
                <source>Br J Radiol</source>
                <volume>75</volume>
                <supplement>Suppl 1</supplement>
                <fpage>A13</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">12036829</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mariani.2003.1253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giona</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villa</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amendola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erba</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buffoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copello</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minichilli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi.</article-title>
                <source>J Nucl Med</source>
                <volume>44</volume>
                <fpage>1253</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">12902415</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.martin.2013.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000fc;le</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smets</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rastetter</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boukhris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loureiro</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mundwiller</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deconinck</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wessner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jornea</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oteyza</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000f6;ls</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mhiri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamari</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kabashi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>92</volume>
                <fpage>238</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">23332916</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.masek.1999.263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masek</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bove</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Short</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norman</surname>
                    <given-names>DK</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Quality of life assessment in adults with type 1 Gaucher disease.</article-title>
                <source>Qual Life Res</source>
                <volume>8</volume>
                <fpage>263</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10472157</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mceachern.2006.719">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McEachern</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nietupski</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuang</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armentano</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hutto</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marshall</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.</article-title>
                <source>J Gene Med</source>
                <volume>8</volume>
                <fpage>719</fpage>
                <lpage>29</lpage>
                <pub-id pub-id-type="pmid">16528760</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mchugh.2004.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McHugh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>E OE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gaucher disease in children: radiology of non-central nervous system manifestations.</article-title>
                <source>Clin Radiol</source>
                <volume>59</volume>
                <fpage>117</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">14746780</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mcneill.2012.853">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McNeill</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schapira</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>A clinical and family history study of Parkinson&#x02019;s disease in heterozygous glucocerebrosidase mutation carriers.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>83</volume>
                <fpage>853</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22577228</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.meikle.1999.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meikle</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopwood</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clague</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Prevalence of lysosomal storage disorders.</article-title>
                <source>JAMA</source>
                <volume>281</volume>
                <fpage>249</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9918480</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.michelakakis.2006.591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Michelakakis</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moraitou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dimitriou</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santamaria</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanchez</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gort</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grinberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dassopoulou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fotopoulos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilageliu</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Homozygosity for the double D409H+H255Q allele in type II Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>29</volume>
                <fpage>591</fpage>
                <pub-id pub-id-type="pmid">16830265</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.micheva.2006.298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Micheva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marinakis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Repa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kouraklis-Symeonidis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vlacha</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anagnostopoulos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoumbos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Symeonidis</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>36</volume>
                <fpage>298</fpage>
                <lpage>307</lpage>
                <pub-id pub-id-type="pmid">16533613</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.migita.2003.524">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Migita</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujimura</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimada</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukunaga</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.</article-title>
                <source>Eur J Pediatr</source>
                <volume>162</volume>
                <fpage>524</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12845529</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mignot.2003.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mignot</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelot</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bessi&#x000e8;res</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daffos</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voyer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menez</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallet Bianco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odent</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Duff</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loget</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costil</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Josset</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roume</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanier</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Billette de Villemeur</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Perinatal-lethal Gaucher disease.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>120A</volume>
                <fpage>338</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">12838552</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.miller.2003.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease.</article-title>
                <source>Clin Genet</source>
                <volume>63</volume>
                <fpage>368</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">12752568</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mistry.2011.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellini</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozsan</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mach Pascual</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helena Solano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spigelman</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villarrubia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watman</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massenkeil</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>A reappraisal of Gaucher disease-diagnosis and disease management algorithms.</article-title>
                <source>Am J Hematol.</source>
                <volume>86</volume>
                <fpage>110</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21080341</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mistry.2015.695">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lukina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Turkia</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amato</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baris</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasouki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghosn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petakov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assouline</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balwani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadjiev</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortega</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shankar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solano</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterschmitt</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <article-title>Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.</article-title>
                <source>JAMA</source>
                <year>2015</year>
                <volume>313</volume>
                <fpage>695</fpage>
                <lpage>706</lpage>
                <pub-id pub-id-type="pmid">25688781</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.mistry.2002.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirrs</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pritzker</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duffy</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meeker</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy.</article-title>
                <source>Mol Genet Metab</source>
                <volume>77</volume>
                <fpage>91</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12359135</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.m_ller.2004.135">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>M&#x000f8;ller</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moestrup</surname>
                    <given-names>SK</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease.</article-title>
                <source>Eur J Haematol</source>
                <volume>72</volume>
                <fpage>135</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14962251</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.montfort.2004.567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Montfort</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilageliu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grinberg</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: Pathogenic changes and "modifier" polymorphisms.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>567</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">15146461</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.neumann.2009.1783">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Sullivan</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parkkinen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guerreiro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paudel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segarane</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revesz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Glucocerebrosidase mutations in clinical and pathologically proven Parkinson&#x02019;s disease.</article-title>
                <source>Brain</source>
                <volume>132</volume>
                <fpage>1783</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19286695</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.orvisky.2002.262">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orvisky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaMarca</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginns</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.</article-title>
                <source>Mol Genet Metab</source>
                <volume>76</volume>
                <fpage>262</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">12208131</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.packman.2006.99">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson Crosbie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riesner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fairley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Psychological complications of patients with Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>29</volume>
                <fpage>99</fpage>
                <lpage>105</lpage>
                <pub-id pub-id-type="pmid">16601875</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.p_mpols.1999.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e0;mpols</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giros</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanmarti</surname>
                    <given-names>FX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanier</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christomanou</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant.</article-title>
                <source>Acta Neuropathol (Berl)</source>
                <volume>97</volume>
                <fpage>91</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9930900</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.park.2003.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orvisky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneski</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamarca</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.</article-title>
                <source>Pediatr Res</source>
                <volume>53</volume>
                <fpage>387</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">12595585</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2003.641">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bathan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>A neurological symptom survey of patients with type I Gaucher disease.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>26</volume>
                <fpage>641</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14707512</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2005.1215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment.</article-title>
                <source>Clin Ther</source>
                <volume>27</volume>
                <fpage>1215</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">16199246</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2007.1645">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hrebicek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.</article-title>
                <source>Clin Ther</source>
                <volume>29</volume>
                <fpage>1645</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">17919546</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2005.70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meere</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I).</article-title>
                <source>Curr Opin Rheumatol</source>
                <volume>17</volume>
                <fpage>70</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15604908</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2000.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Firooznia</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Bone and joint complications related to Gaucher disease.</article-title>
                <source>Curr Rheumatol Rep</source>
                <volume>2</volume>
                <fpage>175</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">11123056</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2004.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giralt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tylki-Szymanska</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Therapeutic goals in the treatment of Gaucher disease.</article-title>
                <source>Semin Hematol</source>
                <volume>41</volume>
                <fpage>4</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">15468045</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.patlas.2002.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patlas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadas-Halpern</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrahamov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years.</article-title>
                <source>Hematol J</source>
                <volume>3</volume>
                <fpage>17</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">11960391</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.poll.2002.a25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poll</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terk</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roca-Espiau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Response of Gaucher bone disease to enzyme replacement therapy.</article-title>
                <source>Br J Radiol</source>
                <volume>75</volume>
                <supplement>Suppl 1</supplement>
                <fpage>A25</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">12036830</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.poorthuis.1999.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleijer</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jong</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Weely</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Diggelen</surname>
                    <given-names>OP</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The frequency of lysosomal storage diseases in The Netherlands.</article-title>
                <source>Hum Genet</source>
                <volume>105</volume>
                <fpage>151</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10480370</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.qi.2001.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Qi</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Molecular and cell biology of acid beta-glucosidase and prosaposin.</article-title>
                <source>Prog Nucleic Acid Res Mol Biol</source>
                <volume>66</volume>
                <fpage>203</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">11051765</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.reczek.2007.770">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reczek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwake</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schr&#x000f6;der</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brondyk</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Patten</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edmunds</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saftig</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.</article-title>
                <source>Cell</source>
                <volume>131</volume>
                <fpage>770</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">18022370</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.robertson.2007.1521">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldblatt</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score.</article-title>
                <source>AJR Am J Roentgenol</source>
                <volume>188</volume>
                <fpage>1521</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17515371</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.roca.2007.132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roca</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mota</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alfonso</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pocovi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease.</article-title>
                <source>Eur J Radiol</source>
                <volume>62</volume>
                <fpage>132</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17161930</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.ron.2005.2387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ron</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horowitz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.</article-title>
                <source>Hum Mol Genet</source>
                <volume>14</volume>
                <fpage>2387</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">16000318</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.rosenbaum.2002.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Cholelithiasis in patients with Gaucher disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>28</volume>
                <fpage>21</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11987238</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.rosenberg.1999.2081">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingma</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzpatrick</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.</article-title>
                <source>Blood</source>
                <volume>93</volume>
                <fpage>2081</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10068682</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.rosenbloom.2005.4569">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kacena</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Gaucher disease and cancer incidence: a study from the Gaucher Registry.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>4569</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15718419</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.rozenberg.2006.204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rozenberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobreira</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>LV</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Detection of 12 new mutations in Gaucher disease Brazilian patients.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>37</volume>
                <fpage>204</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17059888</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.shitrit.2003.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shitrit</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudensky</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>D-dimer assay in Gaucher disease: correlation with severity of bone and lung involvement.</article-title>
                <source>Am J Hematol</source>
                <volume>73</volume>
                <fpage>236</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12879425</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.sidransky.2005.302">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Gaucher disease and parkinsonism.</article-title>
                <source>Mol Genet Metab</source>
                <volume>84</volume>
                <fpage>302</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15781189</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.sidransky.2009.1651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nalls</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aasly</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aharon-Peretz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annesi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbosa</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bar-Shira</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Condroyer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marco</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000fc;rr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eblan</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrer</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fung</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gan-Or</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasser</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gershoni-Baruch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giladi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffith</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurevich</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Januario</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kropp</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee-Chen</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesage</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marder</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mata</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirelman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsui</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuta</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoletti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ottman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orr-Urtreger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>LV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quattrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogaeva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rozenberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samii</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samaddar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulte</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spitz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troiano</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wittstock</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfsberg</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>YR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabetian</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.</article-title>
                <source>N Engl J Med.</source>
                <volume>361</volume>
                <fpage>1651</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">19846850</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.starzyk.2007.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Starzyk</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingma</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The long-term international safety experience of imiglucerase therapy for Gaucher disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>90</volume>
                <fpage>157</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">17079176</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.steet.2007.1376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pine</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornfeld</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.</article-title>
                <source>Biochem Pharmacol</source>
                <volume>73</volume>
                <fpage>1376</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">17217920</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.stein.2010.769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malhotra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haims</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <fpage>769</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">20683668</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.stone.2000a.f163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Callahan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2000a</year>
                <article-title>Type 2 Gaucher disease: the collodion baby phenotype revisited.</article-title>
                <source>Arch Dis Child Fetal Neonatal Ed</source>
                <volume>82</volume>
                <fpage>F163</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10685993</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.stone.2000b.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginns</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasnewich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2000b</year>
                <article-title>Life-threatening splenic hemorrhage in two patients with Gaucher disease.</article-title>
                <source>Am J Hematol</source>
                <volume>64</volume>
                <fpage>140</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10814997</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.stone.1999.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Hydrops fetalis: lysosomal storage disorders in extremis.</article-title>
                <source>Adv Pediatr</source>
                <volume>46</volume>
                <fpage>409</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">10645471</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.stone.2000c.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stone</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orvisky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madike</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2000c</year>
                <article-title>Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>181</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10649495</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.taddei.2009.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Taddei</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kacena</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malhotra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boxer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aleck</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rennert</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                </person-group>
                <article-title>The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.</article-title>
                <source>Am J Hematol.</source>
                <year>2009</year>
                <volume>84</volume>
                <fpage>208</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">19260119</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.takahashi.1998.143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawaishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakuma</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enomoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Enzyme therapy in Gaucher disease type 2: an autopsy case.</article-title>
                <source>Tohoku J Exp Med</source>
                <volume>186</volume>
                <fpage>143</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10223617</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.tayebi.2003a.519">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orvisky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaMarca</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease.</article-title>
                <source>Am J Hum Genet</source>
                <volume>72</volume>
                <fpage>519</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">12587096</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.tayebi.2003b.104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tayebi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stubblefield</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orvisky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaMarca</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?</article-title>
                <source>Mol Genet Metab</source>
                <volume>79</volume>
                <fpage>104</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12809640</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.tylkiszyma_ska.2007.538">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tylki-Szyma&#x00144;ska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czartoryska</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanier</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugowska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millat</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaccaro</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurkiewicz</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Non-neuronopathic Gaucher disease due to saposin C deficiency.</article-title>
                <source>Clin Genet</source>
                <volume>72</volume>
                <fpage>538</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">17919309</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.van_breemen.2007.788">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Breemen</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fost</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voerman</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boot</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rezaee</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1772</volume>
                <fpage>788</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">17499484</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.van_weely.2000.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Weely</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Glucosylceramide: synthesis and degradation.</article-title>
                <source>Gaucher Clin Perspect.</source>
                <year>2000</year>
                <volume>8</volume>
                <fpage>11</fpage>
                <lpage>16</lpage>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.vellodi.2001.319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vellodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Villemeur</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collin-Histed</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erikson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tylki-Szymanska</surname>
                    <given-names>A</given-names>
                  </name>
                  <collab>Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease</collab>
                </person-group>
                <year>2001</year>
                <article-title>Management of neuronopathic Gaucher disease: a European consensus.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>24</volume>
                <fpage>319</fpage>
                <lpage>27</lpage>
                <pub-id pub-id-type="pmid">11486896</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.verghese.2000.389">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verghese</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>RF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rapin</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Myoclonus from selective dentate nucleus degeneration in type 3 Gaucher disease.</article-title>
                <source>Arch Neurol</source>
                <volume>57</volume>
                <fpage>389</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">10714667</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.vom_dahl.2006.1045">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vom Dahl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poll</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients.</article-title>
                <source>Curr Med Res Opin</source>
                <volume>22</volume>
                <fpage>1045</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">16846538</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wan.2006.422">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>36</volume>
                <fpage>422</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16546416</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.weinreb.2007.576">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barranger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prakash-Cheng</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrinar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.</article-title>
                <source>Clin Genet</source>
                <volume>71</volume>
                <fpage>576</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">17539908</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.weinreb.2008.890">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>vom Dahl</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.</article-title>
                <source>Am J Hematol.</source>
                <volume>83</volume>
                <fpage>890</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18819093</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.weinreb.2010.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellini</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannini</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mankin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martins</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawyer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>vom Dahl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A validated disease severity scoring system for adults with type 1 Gaucher disease.</article-title>
                <source>Genet Med.</source>
                <volume>12</volume>
                <fpage>44</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">20027115</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.weinreb.2002.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbloom</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wappner</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.</article-title>
                <source>Am J Med</source>
                <volume>113</volume>
                <fpage>112</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12133749</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wenstrup.2004.1253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moskovitz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oestreich</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.</article-title>
                <source>Blood</source>
                <volume>104</volume>
                <fpage>1253</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15010365</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wenstrup.2007.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kacena</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prakash-Cheng</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hangartner</surname>
                    <given-names>TN</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.</article-title>
                <source>J Bone Miner Res</source>
                <volume>22</volume>
                <fpage>119</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">17032149</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wenstrup.2002.a2">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wenstrup</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roca-Espiau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bembi</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Skeletal aspects of Gaucher disease: a review.</article-title>
                <source>Br J Radiol.</source>
                <volume>75</volume>
                <supplement>Suppl 1</supplement>
                <fpage>A2</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">12036828</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wine.2007.451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wine</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaniv</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy.</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <volume>29</volume>
                <fpage>451</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17609622</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.wong.2004.192">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verma</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mixon</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandberg</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakefield</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lwin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colegial</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Neuropathology provides clues to the pathophysiology of Gaucher disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>82</volume>
                <fpage>192</fpage>
                <lpage>207</lpage>
                <pub-id pub-id-type="pmid">15234332</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.yang.2013.966">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahimpour</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pacak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikejiri</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhuang</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <volume>110</volume>
                <fpage>966</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">23277556</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zhang.2012.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stein</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mistry</surname>
                    <given-names>PK</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation.</article-title>
                <source>Am J Hematol.</source>
                <volume>87</volume>
                <fpage>377</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">22388998</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zimran.2013.134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altarescu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <volume>50</volume>
                <fpage>134</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23085429</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zimran.2010.4651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altarescu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philips</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attias</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jmoudiak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deeb</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhirangi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohn</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.</article-title>
                <source>Blood.</source>
                <volume>115</volume>
                <fpage>4651</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20299511</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zimran.2005.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altarescu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudensky</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrahamov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Survey of hematological aspects of Gaucher disease.</article-title>
                <source>Hematology.</source>
                <year>2005</year>
                <volume>10</volume>
                <fpage>151</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16019462</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zimran.2011.5767">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brill-Almon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chertkoff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petakov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco-Favela</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mu&#x000f1;oz</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solorio-Meza</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amato</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giona</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heitner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbaum</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elstein</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altarescu</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szleifer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashmueli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aviezer</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.</article-title>
                <source>Blood.</source>
                <volume>118</volume>
                <fpage>5767</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">21900191</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.zuckerman.2007.1281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zuckerman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lahad</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shmueli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peleg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orr-Urtreger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy-Lahad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sagi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases.</article-title>
                <source>JAMA</source>
                <volume>298</volume>
                <fpage>1281</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">17878420</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gaucher.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="gaucher.Suggested_Reading.reflist0">
            <ref id="gaucher.REF.beutler.2001">
              <mixed-citation publication-type="book">Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> Chapter 146. 8 ed. New York, NY: McGraw-Hill; 2001:3635-67.</mixed-citation>
            </ref>
            <ref id="gaucher.REF.germain.2004.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gaucher's disease: a paradigm for interventional genetics.</article-title>
                <source>Clin Genet</source>
                <volume>65</volume>
                <fpage>77</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">14984463</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.grabowski.2004.s15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Gaucher disease: lessons from a decade of therapy.</article-title>
                <source>J Pediatr.</source>
                <volume>144</volume>
                <fpage>S15</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15126979</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.grabowski.2014">
              <mixed-citation publication-type="webpage">Grabowski GA, Kolodny EH, Weinreb NJ, Rosenbloom BE, Prakash-Cheng A, Kaplan P, Charrow J, Pastores GM, Mistry PK. Gaucher disease: phenotypic and genetic variation. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chapter 146.1. New York, NY: McGraw-Hill. Avalabile <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/content.aspx?sectionid=62643794">online</ext-link>. 2014. Accessed 8-6-15.</mixed-citation>
            </ref>
            <ref id="gaucher.REF.jmoudiak.2005.178">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jmoudiak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Futerman</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Gaucher disease: pathological mechanisms and modern management.</article-title>
                <source>Br J Haematol</source>
                <volume>129</volume>
                <fpage>178</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">15813845</pub-id>
              </element-citation>
            </ref>
            <ref id="gaucher.REF.pastores.2003.1157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects.</article-title>
                <source>Expert Opin Ther Pat</source>
                <volume>13</volume>
                <fpage>1157</fpage>
                <lpage>72</lpage>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gaucher.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gaucher.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 February (gp) Revision: eliglustat FDA approved for use in the US</p>
            </list-item>
            <list-item>
              <p>19 September 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 July 2011 (cd) Revision: corrections to mutation nomenclature</p>
            </list-item>
            <list-item>
              <p>1 February 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 March 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 November 2005 (gp) Revision: information on miglustat (Management)</p>
            </list-item>
            <list-item>
              <p>2 June 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>18 February 2004 (gp) Revision: Management</p>
            </list-item>
            <list-item>
              <p>8 April 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 July 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 March 2000 (gp) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
